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1. 
ORAL TREATMENT OF HEMOPHILA 
CROSS REFERENCE TO RELATED 
APPLICATION 
This is a national stage under 35 U.S.C. S371 of Interna 
tional Application No. PCT/US02/24544, filed Aug. 2, 2002, 
and claims the benefit of U.S. Provisional application No. 
60/310,150, filed Aug. 3, 2001, which is hereby incorporated 
by reference in its entirety. 
FIELD 
This disclosure relates to methods for treating a subject 
Suffering from an antigen-deficiency which causes a disease, 
by orally administering a therapeutically effective amount of 
the deficient antigen to the Subject, Sufficient to induce oral 
tolerance and relieve symptoms of the disease. In one 
example, the disclosure relates to oral administration of 
clotting factor VIII or IX for treating hemophilia A and B, 
respectively. 
BACKGROUND 
Hemophilia A and B, caused respectively by decreased 
levels of clotting factor VIII (F.VIII) and IX (FIX) levels in 
peripheral blood, are the most common severe inherited 
bleeding disorders. Although purified clotting factors from 
human plasma can be infused into these patients to prevent 
or treat bleeding episodes, this poses the risk of spreading of 
diseases such as Creutzfled-Jakob disease, HIV, and hepa 
titis C. Although recombinant clotting factor preparations 
are available, the supply is insufficient to cover the world 
wide demand. 
As an alternative to generating recombinant clotting fac 
tors in cell culture, the use of transgenic animals as biore 
actors for the production of clinically useful quantities of 
proteins has been proposed. The transgenic animal expresses 
the desired protein in a body fluid, such as milk, from which 
the protein can readily be isolated. Transgenic pigs that 
secrete F.VIII (U.S. Pat. No. 5,880,327 to Lubon et al.) or 
FIX (Van Cott et al. 1999. Genet. Anal. 15:155-60) in their 
milk were generated using gene constructs that have regu 
latory sequences from the gene for mouse whey acidic 
protein (the 4.2 kb 5’ promoter of WAP), in combination 
with the cDNA sequence encoding human F.VIII or F.IX. 
F.VIII pigs secrete 2.7 g/ml of human F.VIII into milk 
(Paleyanda et al. 1997. Nat. Biotech. 15:971), while F.IX 
pigs secrete 2.5 g/L of human F.IX into milk, and the factor 
is biologically active as measured by an activated partial 
thromboplastin time assay (APTT). 
Therefore, large amounts of functional protein can be 
obtained from FIX pigs, which is purified from the milk, and 
Subsequently administered intravenously (i.v.) to a hemo 
philiac patient. However, it has previously been thought that 
oral administration of F.VIII or F.IX results in degradation 
and/or inactivation of the protein due to the acidic and 
enzymatic composition of the stomach. For example, U.S. 
Pat. No. 4,348,384 to Horikoshi et al. teaches the adminis 
tration of an oral composition containing purified F.VIII or 
FIX encapsulated in a liposome along with a protease 
inhibitor, for the purpose of evading gastric inactivation of 
the therapeutic protein. 
One complication that results from i.v. administration of 
F.VIII or F.IX is that up to 25% of hemophiliacs develop 
inhibitors, such as antibodies against F.VIII or F.IX that 
inactivate their procoagulant activity (Fields et al. 2000. 
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Mol. Ther. 3:225-35; Bristol et al. 2001. Hum. Gene Ther. 
12:1651-61; Geet al. 2001. Blood 97:3733-7: Brinkhous et 
al. 1996. Blood 88:2603-10). Most inhibitory antibodies 
develop in severely affected patients who have little or no 
circulating F.IX or F.VIII antigen due to genetic deletion. 
However, patients with a family history of inhibitor devel 
opment, severe disease, older age or higher numbers of 
clotting factor replacement episodes, also have a higher 
incidence of developing these inhibitors (Roberts. 1997. 
Inhibitors and their management. In Hemophilia & Other 
inherited bleeding disorders. Rizza & Lowe, eds. W B 
Saunders Company Ltd., London, p. 365.). The inhibitors 
can completely inhibit the activity of infused clotting factor 
and make further treatment difficult. 
One means of reducing clotting factor antibodies is the 
induction of immune tolerance to the clotting factors. For 
example, Roberts (JAMA 259:84-5, 1988) reviews studies in 
which F.VIII was injected at high concentrations. Although 
some studies reported that the level of anti-factor VIII 
antibodies decreased, due to the high doses required, the 
method was never widely used because it was prohibitively 
expensive. Oral administration of F.VIII as a means to 
prevent the formation of anti-F.VIII antibodies has also been 
attempted, with mixed results. Oral administration of puri 
fied F.VIII to newborn mice did not suppress induction of 
anti-F.VIII antibodies (Kaplan et al. 2000. Semin. Thromb. 
Hemost. 26:173-8). Oral administration of purified F.VIII to 
one of three patients with acquired hemophilia did reduce 
the amount of anti-F.VIII antibodies (Lindgren et al. 2000. 
Thromb. Haemost. 83:632-3). However, there are no teach 
ings that oral administration of clotting factors alone can be 
used to treat hemophilia which is caused by inadequate 
expression of a clotting factor. 
Attempts to induce stable production of the missing 
clotting factors by gene therapy using injections of trans 
fected myoblasts have also been hampered by the host 
immune system which, not being tolerant of the missing 
factor, generates a strong rejection response when intro 
duced (Fields et al. 2000. Mol. Ther. 3:225-35). Thus, 
inhibitory antibodies to the factors and vigorous T cell 
responses to the genetically transfected cells are major 
hurdles to successful treatment of hemophilia. 
Another disadvantage to introduction of a foreign gene 
through the use of a viral vector, is the possibility of an 
elicited immune response against the vector and/or the 
transgene product For example, intramuscular (i.m.) injec 
tion of an adenoviral vector expressing human F.IX into the 
hind limbs of hemophiliac mice results in a CTL response 
against FIX, and destruction of the transduced cells, 
whereas i.m. injection of a less immunogenic vector (adeno 
associated virus, AAV) expressing human F.IX results in 
long-term persistence of the transduced cells and an absence 
of CTL to FIX (Roberts. 1997. Inhibitors and their man 
agement. In Hemophilia & Other inherited bleeding disor 
ders. Rizza & Lowe, eds., W B Saunders Company Ltd., 
London, p. 365.). However, in both cases formation of 
antibodies neutralizes F.IX activity. The same problem 
exists in the canine model of hemophilia B, where anti-F.IX 
antibodies neutralize F.IX activity after gene therapy with 
FIX (Evans et al. 1989. Proc. Natl. Acad. Sci. U S A. 
86:10095-9; Mauser et al. 1996. Blood. 88:3451-5; Herzog 
et al. 1999. Nat. Med. 5:56-63; and Kay et al. 2000. Nat. 
Genet. 24:257-261). 
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SUMMARY OF THE DISCLOSURE 
Although potentially large amounts of functional protein 
can be obtained from F.IX pigs, the current teaching has 
been to purify the factor from the milk, and subsequently 
administer it intravenously (i.v.) to a hemophiliac patient. 
However, it would be advantageous if the protein could be 
delivered orally, as oral administration is more easily 
handled than injection, and may eliminate the need for 
protein purification. In addition, it would be beneficial if oral 
tolerance to clotting factors could be induced by oral admin 
istration of the clotting factor. 
Disclosed herein is a method for treating an antigen 
deficiency disease by orally administering a therapeutically 
effective amount of the deficient antigen. In one non-limiting 
example, the method is a method for increasing hemostasis 
in a subject having a hemophilia caused by inadequate 
expression of a clotting factor, by orally administering a 
therapeutically effective amount of a clotting factor other 
than in a liposome. In another example, the method is a 
method for decreasing the symptoms associated with Gau 
cher disease (such as decreasing hepatosplenomegaly and 
improving bone marrow involvement), in a Subject having 
Gaucher disease caused by decreased expression of acid 
beta-glucosidase, by orally administering a therapeutically 
effective amount of a acid beta-glucosidase. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A is a dot-plot comparing the footpad Swelling in 
mice fed OVA prior to injection (0.1-10 mg OVA) with 
control mice not fed OVA prior to injection (0 mg OVA). 
FIG. 1B shows three dot-plots comparing the amount of 
IL-4, TGF-B, and IFN-Y production in mice fed OVA prior 
to injection, with control mice not fed OVA (water) prior to 
injection. 
FIG. 1C is a graph comparing the amount of T-cell 
proliferation in mice fed OVA prior to injection (0.001-10 
mg OVA) with control mice not fed OVA prior to injection 
(0 mg OVA). 
FIGS. 2A and 2B are graphs comparing the amount of 
T-cell proliferation in (A) normal and (B) hemophilia B mice 
fed human F.IX prior to injection, with control mice not fed 
human F.IX prior to injection. 
FIG. 2C is a graph comparing the level of IgA produced 
in F.IX-fed hemophilia B mice to unfed normal mice. 
FIGS. 3A and 3B are dot plots showing (A) IgG1 and (B) 
IgG2a antibody responses to hF.IX. 
FIG. 4 is a dot plot showing that orally tolerized hemo 
philia B mice show little evidence of inhibitors, as their 
bleeding times are only slightly longer than those of infused 
mice that had not been immunized. 
FIGS. 5A and 5B are graphs comparing the proliferative 
response against sheep casein, in lambs fed (A) sheep milk 
or (B) cow milk. 
FIG. 5C is a dot plot comparing the serum IgG titer to 
sheep casein in lambs raised on sheep milk compared to cow 
milk. 
FIGS. 6A and 6B are a graph and a dot plot, respectively, 
showing that oral feeding of transgenic pig milk containing 
F.IX results in the presence of F.IX in the blood. 
FIG. 7A is a dot plot showing that orally administered 
F.IX remains functional, and corrects the bleeding defect in 
hemophilia B mice. 
FIG. 7B is a graph showing that orally administered FIX 
remains functional, and corrects the bleeding defect in 
hemophilia B mice fed F.IX milk for 2 months. 
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FIGS. 8A and 8B are dot plots showing that orally 
administered F.VIII remains functional, whether adminis 
tered in water or in cow's milk. 
FIG. 8C is a dot plot showing that immunization follow 
ing oral administration of F.VIII does not inhibit F.VIII fed 
Subsequent to the immunization. 
FIG. 8D is a dot plot showing IgG1 and IgG2a antibody 
responses to hF.VIII. 
FIGS. 9A and 9B are graphs comparing the T cell 
response in mice fed F.IX in water or milk showing that oral 
administration of F.IX can be achieved whether adminis 
tered in water or in milk, but that it is more effective if given 
in milk. 
DETAILED DESCRIPTION OF SEVERAL 
EMBODIMENTS 
Abbreviations and Terms 
The following explanations of terms and methods are 
provided to better describe the present disclosure and to 
guide those of ordinary skill in the art in the practice of the 
present disclosure. As used herein and in the appended 
claims, the singular forms “a” or “an or “the include plural 
references unless the context clearly dictates otherwise. For 
example, reference to “a protein’ includes a plurality of such 
proteins and reference to “the antibody' includes reference 
to one or more antibodies and equivalents thereof known to 
those skilled in the art, and so forth. 
Unless explained otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood to one of ordinary skill in the art to which this 
disclosure belongs. 
Antigen: A Substance capable of being the target of 
inducing a specific immune response. 
Antigen-Deficiency Disease: A disease in which a subject 
has an antigen deficiency, such as a protein, which causes the 
disease. Examples of antigen-deficiency diseases include, 
but are not limited to clotting disorders such as hemophilia 
A and B (caused by a deficiency of clotting factor VIII and 
IX, respectively), Von Willebrand’s disease (caused by a 
moderate-to-severe factor VIII deficiency, low-levels of 
factor VIII-related antigen, and insufficient von Willebrand 
factor); and diabetes (caused by a deficiency of insulin). 
Other examples of antigen deficiency diseases include, 
but are not limited to: strokes or heart attacks (deficiency of 
tissue plasminogen activator); emphysema (deficiency of 
alpha-1-antitrypsin); Gaucher disease (deficiency of B-glu 
cosidase), Pompe's disease (deficiency of alpha-1,4-glucosi 
dase); purpura fulminans neonatalis, warfin-induced skin 
necrosis, heparin-induced thrombocytopenia, septic shock, 
and for fibrinolytic therapy (deficiency of protein C) (also 
see U.S. Pat. No. 5,589,604). 
In a particular embodiment, the treatment of such diseases 
can be achieved by orally administering the deficient antigen 
to a Subject having the disease. 
Anti-immune therapy: Administration of agents to a Sub ject having an autoimmune disease to reduce the immune 
response against normal body tissue while leaving intact the 
immune response against micro-organisms and abnormal 
tissues. Examples of agents used to reduce the immune 
response include, but are not limited to: corticosteroids and 
immunosuppressant medications (including prednisolone, 
cyclophosphamide or azathioprine) or cytotoxic agents such 
as cytotoxan or methotrexate. 
Activated partial thromboplastin time (APTT) Assay: An 
assay that measures the time it takes plasma to clot. APTT 
US 7,220,718 B2 
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is the period required for clot formation in recalcified blood 
plasma after contact activation and the addition of platelet 
Substitutes (e.g., brain cephalin or similar phospholipids). In 
normal individuals, the APTT is about 30-40 seconds, and 
the PTT (therapeutic level) is 60 to 70 seconds. A prolonged 
APTT can indicate a deficiency of a number of clotting 
factors including Factors XII, XI, IX, VIII, X, V, and II, and 
fibrinogen. 
Bleeding Time Assay: An assay used to measure the 
amount of time it takes for a subject’s blood to clot. A blood 
pressure cuff is placed on the upper arm and inflated. Two 
incisions are made on the lower arm. These are about 10 mm 
(less than /2 inch) long and 1 mm deep (just deep enough to 
cause minimal bleeding). The blood pressure cuff is imme 
diately deflated. Blotting paper is touched to the cuts every 
30 seconds until the bleeding stops. The length of time it 
takes for the cuts to stop bleeding is recorded. 
In normal, non-hemophiliacs, bleeding stops within about 
one to ten minutes and may vary from lab to lab, depending 
on how the assay is measured. In contrast, severe hemo 
philiacs having less than 1% of normal levels of the appro 
priate clotting factor have a whole blood clotting time of 
greater than 60 minutes. 
In mice, the bleeding time is assayed by transecting the tip 
of the tail and periodically touching a blotting paper until a 
clot is formed at the tip of the tail. Normal bleeding time is 
between 2-4 minutes. In contrast, hemophiliac mice having 
less than 1% of normal levels of the appropriate clotting 
factor have a bleeding time of greater than 15 minutes (see 
FIGS. 7A, 7B, 8A and 8B). 
cDNA (complementary DNA): A piece of DNA lacking 
internal, non-coding segments (introns) and regulatory 
sequences which determine transcription. cDNA can be 
synthesized in the laboratory by reverse transcription from 
messenger RNA extracted from cells. 
Chemical synthesis: An artificial means by which one can 
make a protein or peptide. A synthetic protein or peptide is 
one made by Such artificial means. 
Clotting disorder: A disease resulting in a defect in 
hemostasis in a subject. In one embodiment, it is a disease 
of the blood clotting (coagulation) system in which bleeding 
is prolonged due to inadequate clotting factors in the blood, 
for example inadequate expression of the clotting factor, 
Such as inadequate expression due to a genetic abnormality. 
Normal blood hemostasis is a complex process involving as 
many as 20 different plasma proteins, known as clotting 
factors. Normally, a complex chemical process occurs using 
these clotting factors to form a substance called fibrin that 
stops bleeding. When certain coagulation factors are defi 
cient or missing, the process does not occur normally. 
Bleeding problems can range from mild to severe. 
Some bleeding disorders are present at birth and in some 
instances are inherited disorders. Specific examples include, 
but are not limited to: hemophilia A, hemophilia B, protein 
C deficiency, and Von Willebrand’s disease. Some bleeding 
disorders are developed during certain illnesses (such as 
Vitamin K deficiency, severe liver disease), or treatments 
(such as use of anticoagulant drugs or prolonged use of 
antibiotics). 
Clotting factor: Includes any protein which promotes 
proper hemostasis. In one embodiment, a clotting factor is 
factor VIII (F.VIII) or factor IX (FIX), or a variant or 
fragment thereof which retains its hemostatic activity, for 
example as measured using an APTT assay or a bleeding 
time assay. In another embodiment, when orally adminis 
tered in a therapeutically effective amount, the clotting 
factor increases hemostasis in a subject Suffering from a 
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clotting disorder, Such as hemophilia. In a particular embodi 
ment, a clotting factor is a recombinant clotting factor, 
wherein expression of a DNA encoding the clotting factor in 
a mammal results in the presence of the recombinant clotting 
factor protein in the milk of the transgenic mammal. 
Comprises: A term that means “including.” For example, 
“comprising A or B' means including A or B, or both A and 
B, unless clearly indicated otherwise. 
Deletion: The removal of a sequence of a nucleic acid, for 
example DNA, the regions on either side being joined 
together. 
DNA: Deoxyribonucleic acid. DNA is a long chain poly 
mer which comprises the genetic material of most living 
organisms (some viruses have genes comprising ribonucleic 
acid, RNA). The repeating units in DNA polymers are four 
different nucleotides, each of which comprises one of the 
four bases, adenine, guanine, cytosine and thymine bound to 
a deoxyribose Sugar to which a phosphate group is attached. 
Triplets of nucleotides, referred to as codons, in DNA 
molecules code for amino acid in a polypeptide. The term 
codon is also used for the corresponding (and complemen 
tary) sequences of three nucleotides in the mRNA into which 
the DNA sequence is transcribed. 
Enhance: To improve the quality, amount, or strength of 
Something. In one embodiment, a therapy enhances or 
increases hemostasis in a Subject (Such as a hemophiliac) if 
the subject is more effective at blood clotting (for example, 
their blood clotting time decreases). Such enhancement can 
be measured using the methods disclosed herein, for 
example determining the bleeding time of a subject using an 
APTT or bleeding time assay. 
Factor VIII (F.VIII) F.VIII is a protein required for the 
efficient clotting of blood, and functions in coagulation as a 
cofactor in the activation of factor X by factor IX. A 
concentration of about 100 ng/ml for F.VIII in the blood is 
considered in the normal range. Deficiency of F.VIII is 
associated with hemophilia A, and severe forms of the 
disease can result when a subject has less than about 1% of 
the normal amount of F.VIII (i.e. less than about 1 ng of 
F.VIII per ml of blood). F.VIII is synthesized as a 2351 
amino acid single chain precursor protein, which is pro 
teolytically processed. The human factor VIII gene (186,000 
base-pairs) consists of 26 exons ranging in size from 69 to 
3,106 bp and introns as large as 32.4 kilobases (kb). 
Examples of F.VIII nucleic acid and protein sequences, 
including variants and fragments thereof, and sequences 
from different organisms, are publicly available on Genbank 
(for example see Accession Nos: KO1740, M14113, and 
E00527 (human): AF016234 (canine); and L05573 
(mouse)). 
Gaucher Disease: An autosomal-recessive disorder that 
results from defective activity of acid B-glucosidase. Dis 
ease variants are classified based on the absence or presence 
and severity of neuronopathic involvement. Enzyme therapy 
is currently the treatment of choice in significantly affected 
patients. For example, cerezyme, a recombinantly produced 
mannose-terminated (macrophage-targeted) acid B-glucosi 
dase, is currently used to diminish hepatosplenomegaly and 
improve bone marrow involvement and hematologic find 
ings. However, it is possible that oral administration of 
B-glucosidase using the methods disclosed herein, can be 
used to alleviate one or more symptoms associated with 
Gaucher disease described below. 
Type 2 Gaucher disease is a rare, severe CNS disease that 
leads to death by 2 years of age. 
Type 3 Gaucher disease has highly variable manifesta 
tions in the CNS and viscera. It can present in early 
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childhood with rapidly progressive, massive visceral disease 
and slowly progressive to static CNS involvement; in ado 
lescence with dementia; or in early adulthood with rapidly 
progressive, uncontrollable myoclonic seizures and mild 
visceral disease. Visceral disease in type 3 is nearly identical 
to that in type 1, but is generally more severe. Early CNS 
findings may be limited to defects in lateral gaze tracking, 
which may remain static for decades. Mental retardation can 
be slowly progressive or static. 
Type 1 Gaucher disease is a highly variable nonneurono 
pathic disease. Younger patients tend to have a greater 
degree of hepatosplenomegaly and accompanying blood 
cytopenias. Older patients have a greater tendency for 
chronic bone disease. Hepatosplenomegaly occurs in virtu 
ally all symptomatic patients and can be minor or massive. 
Accompanying anemia and thrombocytopenia are variable 
and not linearly related to liver or spleen volume. Severe 
liver dysfunction is unusual, though minor liver function 
abnormalities are common. Splenic infarctions can resemble 
an acute abdomen. Pulmonary hypertension and alveolar 
Gaucher cell accumulation are uncommon, but life-threat 
ening. 
Though it is more common in adult patients, clinically 
evident skeletal disease in children can be devastating, 
resulting in massive destruction of the axial and peripheral 
skeleton. All patients with Gaucher disease have non-uni 
form infiltration of bone marrow by lipid-laden macroph 
ages, termed Gaucher cells. This can lead to marrow packing 
with Subsequent infarction, ischemia, necrosis, and cortical 
bone destruction. Bone marrow involvement spreads from 
proximal to distal in the limbs and can involve the axial 
skeleton extensively, causing vertebral collapse. In addition 
to bone marrow involvement, bone remodeling is defective, 
with loss of total bone calcium leading to osteopenia, 
osteonecrosis, avascular infarction, and vertebral compres 
sion fractures and spinal cord involvement. Aseptic necrosis 
of the femoral head is common, as is fracture of the femoral 
neck. 
Affected patients experience chronic, ill-defined bone 
pain that can be debilitating. Some patients have one or more 
“bone crises' in their lifetimes that are associated with 
localized, excruciating pain, and, on occasion, local 
erythema, fever, and leukocytosis. Any bone can be 
involved, though the femurs and vertebral bodies are 
affected most often. These crises represent acute infarctions 
of bone, as evidenced in nuclear scans by localized absent 
uptake of pyrophosphate agents. X-rays are usually negative 
initially but may show lytic lesions 4 to 6 months after the 
acute phase. 
The diagnosis of Gaucher disease is established by dem 
onstrating decreased acid B-glucosidase activity (0 to 20% 
of normal) in nucleated cells. The enzyme is not present in 
bodily fluids. The sensitivity of enzyme testing is poor for 
detecting heterozygous carriers; molecular testing is pre 
ferred when the mutations are known. Four common muta 
tions account for ~90 to 95% of the mutations in affected 
patients: N370S (1226G), 84GG (a G insertion at cDNA 
position 84), L444P (1448C), and IVS-2 (an intron 2 splice junction mutation). Genotype/phenotype studies indicate a 
significant correlation, though not absolute, between disease 
type and severity and the acid B-glucosidase genotype. 
Factor IX (F.IX): F.IX is a vitamin K-dependent protein 
required for the efficient clotting of blood, and functions in 
coagulation as an activator of factor X. A concentration of 
about 1-5 lug/ml of F.IX in the blood is considered in the 
normal range. Deficiency of F.IX is associated with hemo 
philia B, and severe cases result when the concentration of 
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FIX is less than about 1% of the normal concentration of 
F.IX (i.e. less than about 0.01-0.05ug F.IX per ml of blood). 
Canine F.IX possesses 86% identity at the amino-acid level 
with human F.IX (Evans et al. 1989. Blood 74:207-12). F.IX 
nucleic acid and protein sequences, including variants and 
fragments thereof, and sequences from different organisms, 
are publicly available (for example see Kurachi et al., 1982. 
Proc. Nat. Acad. Sci. U.S.A. 79(21):6461-4; Genbank Acces 
sion Nos: JOO136, XM 045316, KO2402, J00137, and 
M11309 (human) and M21757 and M33826 (canine)). 
Hemophilia: A blood coagulation disorder caused by a 
deficient clotting factor activity, which decreases hemosta 
sis. Severe forms result when the concentration of clotting 
factor is less than about 1% of the normal concentration of 
the clotting factor in a normal Subject. In some subjects, 
hemophilia is due to a genetic mutation which results in 
impaired expression of a clotting factor. In others, hemo 
philia is an auto-immune disorder, referred to as acquired 
hemophilia, in which the antibodies which are generated 
against a clotting factor in a subject result in decreased 
hemostasis. 
Hemophilia A results from a deficiency of functional 
clotting factor VIII (F.VIII), while hemophilia B results from 
a deficiency of functional clotting factor IX (F.IX). These 
conditions which are due to a genetic mutation are caused by 
an inherited sex-linked recessive trait with the defective 
gene located on the X chromosome, and this disease is 
therefore generally found only in males. The severity of 
symptoms can vary with this disease, and the severe forms 
become apparent early on. Bleeding is the hallmark of the 
disease and typically occurs when a male infant is circum 
cised. Additional bleeding manifestations make their appear 
ance when the infant becomes mobile. Mild cases may go 
unnoticed until later in life when they occur in response to 
Surgery or trauma. Internal bleeding may happen anywhere, 
and bleeding into joints is common. 
Hemophiliac: A Subject having a hemophilia. 
Hemostasis: Arrest of bleeding blood by blood clot for 
mation. When hemostasis is increased, it is increased rela 
tive to hemostasis in a Subject prior to orally administering 
a therapeutically effective amount of the appropriate clotting 
factor to the Subject. In one embodiment, when hemostasis 
increases in a Subject with hemophilia, the blood clotting 
time decreases. Blood clotting time is the length of time it 
takes for peripheral blood to clot using an activated partial 
thromboplastin time assay (APTT, see EXAMPLE 9) or by 
measuring bleeding time (see above and EXAMPLE 5). In 
a particular embodiment, the blood clotting time decreases 
by at least 50%, for example at least 60%, at least 70%, at 
least 75%, at least 80%, at least 90%, at least 95%, at least 
98%, at least 99% or even about 100% (i.e. the blood 
clotting time is similar to what is observed for a normal 
subject) when compared to the blood clotting time of the 
Subject prior to orally administering to the Subject a thera 
peutically effective amount of the appropriate clotting factor. 
In yet another embodiment, the blood clotting time in the 
affected subject is corrected to about 90% of a normal 
subject, for example to about 95%, for example about 100%, 
after oral administration of a therapeutically effective 
amount of the appropriate clotting factor. 
Impaired Expression: Decreased expression of a DNA or 
protein resulting in a deficiency of the protein in a Subject. 
Such a protein deficiency may cause disease in the Subject. 
Isolated: An isolated nucleic acid has been substantially 
separated or purified away from other nucleic acid 
sequences in the cell of the organism in which the nucleic 
acid naturally occurs, i.e., other chromosomal and extrach 
US 7,220,718 B2 
romosomal DNA and RNA. The term "isolated thus 
encompasses nucleic acids purified by standard nucleic acid 
purification methods. The term also embraces nucleic acids 
prepared by recombinant expression in a host cell as well as 
chemically synthesized nucleic acids. 
Liposome: A closed, solvent-filled vesicle bounded by a 
single bilayer of phospholipids, which is impermeable to 
many Substances. In one embodiment, a liposome has the 
properties described in U.S. Pat. No. 4,348,384 to Horikoshi 
et al. (herein incorporated by reference). 
Mammal: This term includes both human and non-human 
mammals. Similarly, the terms “patient,” “subject,” and 
“individual' includes both human and veterinary subjects. 
Examples of mammals include, but are not limited to: 
humans, pigs, cows, goats, cats, dogs, rabbits and mice. 
Normal Cells: Non-disease cells. In one embodiment, 
normal cells are cells obtained from a healthy subject, for 
example as compared to a hemophilic or diabetic Subject. 
Normal Subject: A subject who does not have an antigen 
deficiency disease. For example, a Subject who does not 
have hemophilia A or B. 
Oligonucleotide: A linear polynucleotide sequence of up 
to about 200 nucleotide bases in length, for example a 
polynucleotide (such as DNA or RNA) which is at least 
about 6 nucleotides, for example at least 15, 50, 100 or 200 
nucleotides long. 
Operably linked: A first nucleic acid sequence is operably 
linked with a second nucleic acid sequence when the first 
nucleic acid sequence is placed in a functional relationship 
with the second nucleic acid sequence. For instance, a 
promoter is operably linked to a coding sequence if the 
promoter affects the transcription or expression of the cod 
ing sequence. Generally, operably linked DNA sequences 
are contiguous and, where necessary to join two protein 
coding regions, in the same reading frame. 
ORF (open reading frame): A series of nucleotide triplets 
(codons) coding for amino acids without any termination 
codons. These sequences are usually translatable into a 
peptide. 
Oral administration: A method of delivering an agent to a 
Subject by mouth. In one embodiment, oral administration is 
achieved by feeding the agent to the Subject. In a particular 
embodiment, the agent is an antigen, such as a protein, for 
example F.VIII or F.IX. The agent can be delivered with one 
or more pharmaceutically acceptable carriers which are not 
liposomes. In addition, the agent and one or more therapeu 
tically effective pharmaceutical compounds can be admin 
istered concurrently or separately. 
Oral tolerance: A method of downregulating an immune 
response in a Subject by orally administering an antigen (i.e. 
by feeding) to the subject. Oral tolerance is characterized by 
decreased levels of systemic antibody production, as well as 
decreased delayed type hypersensitivity responses (DTH), T 
cell proliferation, cytotoxic responses and graft rejection 
(Alpan et al. 2001. J. Immunol. 166:4843-52; Chen et al. 
1995. Nature 376:177-80; Weiner. 1997. Imm. Today. 7:335 
44; Sayegh et al. 1992. Transplantation. 53:163-6). 
The tolerogenic effect due to administration of high doses 
oral antigen is deletion of antigen-specific T cells by apop 
tosis (Weiner. 1997. Imm. Today, 7:335-44). Administration 
of low doses of oral antigen induces a Switch in effector class 
such that Th1 type responses (DTH, cytotoxicity, graft 
rejection and complement fixing antibodies) are Supplanted 
by Th3 type responses (the production of IL-4, IL 10, TGF-B 
and, occasionally, secretory IgA) (Weiner. 1997. Imm. 
Today. 7:335-44). Low dose oral tolerance reduces the 
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severity of EAE (Fields et al. 2000. Molecular Therapy. 
3:225-35) and enables the acceptance of foreign transplants. 
Promoter: An array of nucleic acid control sequences 
which direct transcription of a nucleic acid. A promoter 
includes necessary nucleic acid sequences near the start site 
of transcription, Such as, in the case of a polymerase II type 
promoter, a TATA element. A promoter also optionally 
includes distal enhancer or repressor elements which can be 
located as much as several thousand base pairs from the start 
site of transcription. 
Purified: The term purified does not require absolute 
purity; rather, it is intended as a relative term. Thus, for 
example, a purified clotting factor preparation is one in 
which the factor is more pure than the factor in its natural 
environment within a cell. For example, a preparation of a 
clotting factor protein is purified if the protein represents at 
least 50%, for example at least 70%, of the total protein 
content of the preparation. Methods for purification of 
proteins and nucleic acids are well known in the art. 
Examples of methods that can be used to purify an antigen, 
Such as a clotting factor include, but are not limited to the 
methods disclosed in Sambrook et al. (Molecular Cloning: 
A Laboratory Manual, Cold Spring Harbor, N.Y., 1989, Ch. 
17); U.S. Pat. No. 6,005,082 to Smeds; EP 0294.910 to van 
Ooyen et al.: 
Recombinant: A recombinant nucleic acid is one that has 
a sequence that is not naturally occurring or has a sequence 
that is made by an artificial combination of two otherwise 
separated segments of sequence. This artificial combination 
is often accomplished by chemical synthesis or, more com 
monly, by the artificial manipulation of isolated segments of 
nucleic acids, e.g., by genetic engineering techniques. A 
recombinant protein is one that results from expressing a 
recombinant nucleic acid encoding the protein. 
RT: Room temperature 
Sample: Biological samples containing genomic DNA, 
cDNA, RNA, or protein obtained from the cells of a subject, 
Such as those present in peripheral blood, urine, saliva, tissue 
biopsy, Surgical specimen, fine needle aspriates, amniocen 
tesis samples and autopsy material. 
Sequence identity/similarity: The identity/similarity 
between two or more nucleic acid sequences, or two or more 
amino acid sequences, is expressed in terms of the identity 
or similarity between the sequences. Sequence identity can 
be measured in terms of percentage identity; the higher the 
percentage, the more identical the sequences are. Sequence 
similarity can be measured in terms of percentage similarity 
(which takes into account conservative amino acid substi 
tutions); the higher the percentage, the more similar the 
Sequences are. 
Methods of alignment of sequences for comparison are 
well known in the art. Various programs and alignment 
algorithms are described in: Smith & Waterman, Adv. Appl. 
Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 
48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. 
USA 85:2444, 1988: Higgins & Sharp, Gene, 73:237-44, 
1988: Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et 
al., Nuc. Acids. Res. 16:10881-90, 1988; Huang et al. 
Computer Appls. in the Biosciences 8, 155-65, 1992; and 
Pearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschulet 
al., J. Mol. Biol. 215:403-10, 1990, presents a detailed 
consideration of sequence alignment methods and homology 
calculations. 
The NCBI Basic Local Alignment Search Tool (BLAST) 
(Altschulet al., J. Mol. Biol. 215:403-10, 1990) is available 
from several sources, including the National Center for 
Biological Information (NCBI, National Library of Medi 
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cine, Building 38A, Room 8N805, Bethesda, Md. 20894) 
and on the Internet, for use in connection with the sequence 
analysis programs blastp, blastin, blastX, thlastn and thlastX. 
Additional information can be found at the NCBI web site. 
For comparisons of amino acid sequences of greater than 
about 30 amino acids, the Blast 2 sequences function is 
employed using the default BLOSUM62 matrix set to 
default parameters, (gap existence cost of 11, and a per 
residue gap cost of 1). When aligning short peptides (fewer 
than around 30 amino acids), the alignment should be 
performed using the Blast 2 sequences function, employing 
the PAM30 matrix set to default parameters (open gap 9. 
extension gap 1 penalties). Proteins with even greater simi 
larity to the reference sequence will show increasing per 
centage identities when assessed by this method. Such as at 
least 70%, 75%, 80%, 85%, 90%, 95%, or even 99% 
sequence identity. When less than the entire sequence is 
being compared for sequence identity, homologs will typi 
cally possess at least 75% sequence identity over short 
windows of 10-20 amino acids, and can possess sequence 
identities of at least 85%, 90%. 95% or 98% depending on 
their identity to the reference sequence. Methods for deter 
mining sequence identity over Such short windows are 
described at the NCBI web site. 
Protein homologs are typically characterized by posses 
sion of at least 70%, such as at least 75%, 80%, 85%, 90%, 
95% or even 98% sequence identity, counted over the 
full-length alignment with the amino acid sequence using 
the NCBI Basic Blast 2.0, gapped blastp with databases such 
as the nr or Swissprot database. Queries searched with the 
blastin program are filtered with DUST (Hancock and Arm 
strong, 1994, Comput. Appl. Biosci. 10:67-70). Other pro 
grams use SEG. 
One of skill in the art will appreciate that these sequence 
identity ranges are provided for guidance only; it is possible 
that strongly significant homologs could be obtained that fall 
outside the ranges provided. Provided herein are the peptide 
homologs described above, as well as nucleic acid mol 
ecules that encode such homologs. 
Nucleic acid sequences that do not show a high degree of 
identity may nevertheless encode identical or similar (con 
served) amino acid sequences, due to the degeneracy of the 
genetic code. Changes in a nucleic acid sequence can be 
made using this degeneracy to produce multiple nucleic acid 
molecules that all encode Substantially the same protein. 
Such homologous peptides can, for example, possess at least 
75%, 80%, 90%. 95%, 98%, or 99% sequence identity 
determined by this method. When less than the entire 
sequence is being compared for sequence identity, homologs 
can, for example, possess at least 75%, 85% 90%. 95%, 98% 
or 99% sequence identity over short windows of 10-20 
amino acids. Methods for determining sequence identity 
over such short windows can be found at the NCBI web site. 
One of skill in the art will appreciate that these sequence 
identity ranges are provided for guidance only; it is possible 
that significant homologs or other variants can be obtained 
that fall outside the ranges provided. 
Subject: Living multicellular vertebrate organisms, a cat 
egory which includes, both human and veterinary Subjects 
for example, mammals, rodents, and birds. 
Therapeutically Effective Amount: An amount sufficient 
to achieve a desired biological effect, for example an amount 
that is effective to increase hemostasis. In particular 
examples, it is a concentration of clotting factor. Such as 
F.VIII or F.IX, effective to increase hemostasis, such as in a 
Subject to whom it is administered. Such as a hemophiliac. 
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In other examples, it is an amount effective to increase 
hemostasis by more than a desired amount. 
In one embodiment, the therapeutically effective amount 
also includes a quantity of clotting factor (such as a clotting 
factor protein or nucleic acid) sufficient to achieve a desired 
effect in a Subject being treated. For instance, these can be 
an amount necessary to improve signs and/or symptoms a 
disease Such as hemophilia, for example by increasing 
hemostasis. 
An effective amount of a clotting factor can be adminis 
tered in a single dose, or in several doses, for example daily, 
during a course of treatment. However, the effective amount 
of clotting factor will be dependent on the source of clotting 
factor administered (i.e. clotting factor isolated from a blood 
sample versus recombinant clotting factor expressed in 
milk), the subject being treated, the severity and type of the 
condition being treated, and the manner of administration 
clotting factor. For example, a therapeutically effective 
amount of clotting factor can vary from about 0.01 mg/kg 
body weight to about 5 g/kg body weight, for example, at 
least 5 mg/kg daily, for example at least 50 mg/kg daily. In 
other embodiment, it is a concentration of F.VIII, when 
orally administered, which results in a blood concentration 
of greater than about 1 ng F.VIII per ml blood, for example 
greater than about 10 ng per ml, for example about 100 ng 
per ml. In yet another embodiment, it is a concentration of 
F.IX, when orally administered, which results in a blood 
concentration of greater than about 0.01-0.05ug F.IX per ml 
blood, for example greater than about 0.1-0.5 ug per ml, for 
example about 1-5 ug per ml. 
The methods disclosed herein have equal application in 
medical and veterinary settings. Therefore, the general term 
“subject being treated is understood to include all animals 
(e.g. humans, apes, dogs, cats, horses, and cows) that require 
an increase in the desired biological effect, Such as enhanced 
hemostasis Susceptible to clotting factor-mediated modula 
tion. 
Therapeutically effective dose: A dose of antigen suffi 
cient to increase the amount of that antigen in a Subject to 
whom it is administered, resulting in a regression of a 
pathological condition, or which is capable of relieving 
signs or symptoms caused by the condition. In a particular 
embodiment, it is a dose of clotting factor Sufficient to 
increase hemostasis in a hemophiliac. 
Transformed: A transformed cell is a cell into which has 
been introduced a nucleic acid molecule by molecular 
biology techniques. As used herein, the term transformation 
encompasses all techniques by which a nucleic acid mol 
ecule might be introduced into Such a cell, including trans 
fection with viral vectors, transformation with plasmid vec 
tors, and introduction of naked DNA by electroporation, 
lipofection, and particle gun acceleration. 
Transgenic Cell: Transformed cells which contain for 
eign, non-native DNA. 
Transgenic mammal: Transformed mammals which con 
tain foreign, non-native DNA. In one embodiment, the 
non-native DNA is an antigen, such as human F.VIII or 
human F.IX. In a particular embodiment, a transgenic mam 
mal expresses a recombinant clotting factor in its milk. In 
yet another embodiment, the transgenic animal is a pig 
expressing recombinant human F.VIII or F.IX in its milk. 
One skilled in the art will understand that any mammal can 
be used, including, but not limited to pigs, cows, goats, 
sheep, rats, mice, rabbits, dogs, cats, and primates. 
Variants or fragments or fusion proteins: The production 
of protein which is orally administered can be accomplished 
in a variety of ways (for example see EXAMPLES 15 and 
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16). DNA sequences which encode for a protein or fusion 
protein, or a fragment or variant of a protein (for example a 
fragment or variant having 80%, 90% or 95% sequence 
identity to a blood clotting factor) can be engineered to allow 
the protein to be expressed in eukaryotic cells or organisms, 5 
bacteria, insects, and/or plants. To obtain expression, the 
DNA sequence can be altered and operably linked to other 
regulatory sequences. The final product, which contains the 
regulatory sequences and the therapeutic protein, is referred 
to as a vector. This vector can be introduced into eukaryotic, 10 
bacteria, insect, and/or plant cells. Once inside the cell the 
vector allows the protein to be produced. 
A fusion antigen comprising a protein, such as F.VIII or 
FIX (or variants, polymorphisms, mutants, or fragments 
thereof) linked to other amino acid sequences that do not 15 
inhibit the desired activity of the protein, for example the 
ability to increase hemostasis. In one embodiment, the other 
amino acid sequences are no more than 10, 20, 30, or 50 
amino acid residues in length. 
One of ordinary skill in the art will appreciate that the 20 
DNA can be altered in numerous ways without affecting the 
biological activity of the encoded protein. For example, PCR 
can be used to produce variations in the DNA sequence 
which encodes an antigen. Such variants can be variants 
optimized for codon preference in a host cell used to express 25 
the protein, or other sequence changes that facilitate expres 
S1O. 
Vector: A nucleic acid molecule as introduced into a host 
cell, thereby producing a transformed host cell. A vector can 
include nucleic acid sequences that permit it to replicate in 30 
the host cell. Such as an origin of replication. A vector can 
also include one or more selectable marker genes and other 
genetic elements known in the art. 
Additional definitions of terms commonly used in 
molecular genetics can be found in Benjamin Lewin, Genes 35 
Vpublished by Oxford University Press, 1994 (ISBN 0-19 
854287-9); Kendrew et al (eds.), The Encyclopedia of 
Molecular Biology, published by Blackwell Science Ltd., 
1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), 
Molecular Biology and Biotechnology: a Comprehensive 40 
Desk Reference, published by VCH Publishers, Inc., 1995 
(ISBN 1-56081-569-8). 
Disclosed herein is a method for increasing hemostasis in 
a subject having a hemophilia by orally administering to the 
Subject a therapeutically effective amount of a clotting factor 45 
not present in a liposome, Sufficient to induce oral tolerance 
and Supply exogenous clotting factor to the Subject. In one 
embodiment, hemophilia is a result of impaired expression 
of a clotting factor. In yet another embodiment, increasing 
hemostasis comprises decreasing blood clotting time. For 50 
example, blood clotting time can be decreased by at least 
50%, for example at least 60%, at least 70%, at least 80%, 
at least 85%, at least 90%, at least 95%, at least 98%, or even 
at least 99% compared to a blood clotting time of an 
untreated hemophilic subject. The blood clotting time can be 55 
measured using an activated partial thromboplastin time 
(APTT) assay or by a bleeding time assay. 
In another embodiment, the clotting factor is administered 
in absence of an anti-immune therapy. In a particular 
embodiment, a therapeutically effective amount of a clotting 60 
factor is a daily dose of at least 5 mg of clotting factor per 
kg of Subject, for example at least 50 mg of clotting factor 
per kg of Subject. The clotting factor can be administered 
daily or every other day. The subject to be treated can be a 
mammal, for example a human or dog. The hemophilia can 65 
be hemophilia A and the clotting factor F.VIII, or hemophilia 
B and the clotting factor F.IX. In one embodiment, a 
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therapeutically effective amount of F.VIII is at least 5 mg of 
clotting factor per 1 kg of Subject daily and a therapeutically 
effective amount of F.IX is at least 50 mg of clotting factor 
per 1 kg of Subject daily. 
In a particular embodiment, oral administration is 
achieved by feeding the subject a therapeutically effective 
amount of the clotting factor. For example, the clotting 
factor can be a recombinant clotting factor present in milk of 
a transgenic mammal, which is fed to a hemophiliac. In one 
embodiment, the clotting factor. Such as F.IX, is present in 
milk obtained from a transgenic pig expressing the clotting 
factor, such as recombinant F.IX. The clotting factors can be 
present in at least one pharmaceutically effective carrier, 
Such as water or milk. 
The methods disclosed herein can further include admin 
istering to a Subject an isolated recombinant nucleic acid 
molecule encoding a clotting factor, such that the clotting 
factor is expressed in the Subject. 
Also disclosed herein is a method for increasing hemo 
Stasis in a Subject having a hemophilia, which includes, and 
in some examples consists of orally administering to the 
Subject a therapeutically effective amount of a clotting factor 
and at least one pharmaceutically acceptable carrier which is 
not a liposome. In other examples, the pharmaceutical 
compositions disclosed herein (including clotting factors) 
can be administered in combination, or separately, with one 
or more other therapeutic treatments, such as other agents 
that increase hemostasis. 
A method is also disclosed for orally administering a 
recombinant clotting factor to a Subject for treatment of a 
hemophilia by orally administering milk containing recom 
binant clotting factor to the subject at a therapeutically 
effective amount Such that hemostasis in the Subject is 
increased, thereby treating the hemophilia. In one embodi 
ment, the milk contains at least 2 g recombinant clotting 
factor/liter of milk. At this concentration, a 70 kg human 
would drink about 0.175 liters of milk daily to achieve an 
effective dose of about at least 5 mg/kg or about 1.75 liters 
of milk to achieve an effective dose of about at least 50 
mg/kg. The milk can be obtained from a transgenic mammal, 
Such as a pig which expresses the clotting factor (or other 
therapeutic protein) in its milk. In a particular example, the 
milk can contain recombinant F.IX antigen at a concentra 
tion of about 2 g per liter, for example about 2.5g per L. 
either expressed in the milk or exogenously added to the 
milk. 
Also disclosed herein is a method for orally administering 
a recombinant clotting factor to a subject for treatment of a 
hemophilia by expressing the clotting factor in a mammal 
such that the clotting factor is expressed in milk of the 
mammal and orally administering the milk in which the 
clotting factor has been expressed to the Subject at a thera 
peutically effective amount such that blood clotting time in 
the subject is reduced, thereby treating the hemophilia. In a 
particular embodiment, the hemophilia is hemophilia B and 
the clotting factor is F.IX. 
Further disclosed is a method for orally administering a 
recombinant F.IX protein to a subject for treatment of 
hemophilia B by orally administering milk containing 
recombinant F.IX protein at a therapeutically effective 
amount Such that blood clotting time in the Subject is 
reduced, thereby treating the hemophilia B. 
Also disclosed is a method of orally administering to a 
hemophiliac a therapeutically effective amount of a clotting 
factor protein sufficient to induce oral tolerance to the 
clotting factor protein and Supply exogenous clotting factor 
protein to the hemophiliac, wherein the clotting factor 
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protein is not present in a liposome, and wherein oral 
tolerance prepares the hemophiliac for in Vivo expression of 
a clotting factor gene. In a particular embodiment, the 
clotting factor is F.VIII or FIX. 
Disclosure of certain specific examples is not meant to 
exclude other embodiments. 
EXAMPLE 1. 
Ovalbumin Oral Tolerance 
This example describes the methods used to induce oral 
tolerance in mice to ovalbumin (OVA) by first orally admin 
istering OVA prior to immunization with OVA. Similar 
methods can be used to test any antigen of interest, Such as 
F.VIII, FIX, protein C, or insulin, in any animal/subject of 
interest. 
Normal B10 mice were fed OVA by adding the protein to 
their drinking water for eight days at concentrations of 0.02, 
0.2 or 2 mg/ml. The mice drank an average of 5.2 ml/mouse? 
day. Therefore, the doses were 0.1, 1.0 and 10 mg/mouse/ 
day of OVA. Control mice only drank water. Two days after 
the last feeding, all mice were immunized with 50 ug OVA 
in complete Freund's adjuvant (CFA) (Sigma, St. Louis, 
Mo.) in the left footpad. Seven days later, footpad swelling 
was determined by measuring the thickness of the footpad. 
Measurement of the right (un-injected) footpad served as an 
untreated control. The footpad swelling responses were 
compared between injected, OVA-fed mice and injected, 
non-OVA fed control mice. As shown in FIG. 1A, the 
footpads of OVA-fed mice swelled less than those of the 
unfed group. 
To compare the amount of IL4, TGF-B, and IFN-Y pro 
duction, mice were fed 0.1 mg OVA for 10 days, then 
immunized as described above. Seven days after immuni 
Zation, lymph nodes draining the immunization site were 
harvested and cultured in vitro with 100 ug/ml OVA. The 
culture was carried in 96 well round bottom plates, with 
500,000 cells per well, for four days. For the last 8 hours of 
the culture, cells were pulsed with tritiated thymidine to 
assay for proliferation using a beta plate cell harvester. For 
IL-4 and IFN-y, supernatants were assayed at day four. For 
TGF-B, after four days in culture, cells were washed, 
restimulated with APC and OVA in serum-free medium, and 
Supernatants assayed at day three. ELISA assays were per 
formed using commercially available kits from Endogen 
(Rockford, Ill.), according to the manufacturers instruc 
tions. As shown in FIG. 1B, OVA-fed mice made high levels 
of IL-4 and TGF-B, but low levels of IFN-Y compared to 
mice in the unfed group. 
To compare the amount of T-cell proliferation, mice were 
fed doses of OVA ranging from 0.001-10 mg every-other 
day for five feeds and immunized with 50 ug OVA in CFA. 
Seven days after immunization, lymph nodes draining the 
immunization site were harvested by Surgical dissection. 
CD4 T-cells were purified from the lymph nodes and cul 
tured in vitro with irradiated spleen cells and a graded 
concentration of OVA as described above. As shown in FIG. 
1C, T cells in the draining lymph nodes of OVA-fed mice 
proliferated less than those mice in the unfed group. Since 
T cells in lymph nodes proliferate in response to regional 
antigenic stimulation, the reduction in T cell proliferation 
was a measure of decreased antigenic stimulation from OVA 
injection in the footpad. 
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EXAMPLE 2 
Factor IX Oral Tolerance 
This example describes experiments in which mice devel 
oped oral tolerance to FIX by orally administering F.IX 
prior to immunization with F.IX, using the methods 
described in EXAMPLE 1. 
Briefly, normal B10. A mice (F.IX-/+) or hemophilia B 
mice (F.IX-/-) were fed transgenic human F.IX (hFIX) in 
pig milk (see EXAMPLE 5) or control pig milk (no hF.IX) 
every other day for three weeks. Individual mice drank about 
4 ml (10 ugh F.IX/day/mouse) of the milk at each time. Two 
days after the last feeding, all mice were immunized with 50 
ug human F.IX emulsified in CFA at the base of the tail. 
Eight days later, the amount of T cell proliferation was 
determined by culturing T-cells from the lymph nodes with 
graded concentrations of human F.IX (purified from the 
transgenic pig milk) for four days using the methods 
described in EXAMPLE 1. As shown in FIGS. 2A and 2B, 
feeding mice human F.IX had a similar effect to the result 
observed in EXAMPLE 1 for OVA, in that it decreased T 
cell proliferation upon Subsequent immunization with 
human F.IX in CFA. 
To demonstrate that oral administration of F.IX induces 
local immunity, hemophiliac B mice were fed transgenic 
FIX in milk (see EXAMPLE 5) while normal mice did not 
receive F.IX, as described above. Subsequently the level of 
intestinal IgA to FIX was measured by collecting stool 
samples, dissolving them in PBS, and assaying for IgA using 
standard ELISA methods. As shown in FIG. 2C, feeding 
FIX induces local immunity as measured by the production 
of secretory IgA. 
EXAMPLE 3 
Antibodies Produced by Orally Tolerized 
Hemophilia B Mice Do Not Result in Clinical 
Resistance to Infused FIX 
To measure IgG1 and IgG2a antibodies specific for hF.IX, 
plates were coated with hE.IX (10 g/ml in PBS) then 
blocked with BSA overnight. After five washes, serum 
samples from the normal and hemophilia B mice fed as 
described in EXAMPLE 2 were added and incubated for two 
hours. The plates were then washed and Subsequently incu 
bated with HRP-conjugated goat-anti-mouse IgG1 and 
IgG2a for two hours, followed by TMP for color develop 
ment, and plates Subsequently read on an ELISA plate 
reader. As shown in FIGS. 3A and 3B, whereas unfed control 
mice made strong IgG2a antibodies, mice fed with hF.IX 
made no detectable IgG2a, but did produce IgG1. 
Therefore, in normal mice, oral administration of human 
F.IX did not completely inhibit the production of small 
amounts of antibodies after immunization in CFA, as 
detected in ELISA assays, although it caused a shift from 
IgG2a to IgG1 (FIGS. 3A and 3B). However, CFA is the 
strongest adjuvant known, and may elicit antibody produc 
tion that would not occur under conditions that more closely 
resemble a clinical situation. However, antibodies detectable 
in ELISA assays may bind to denatured proteins, but may 
not act as inhibitors of the native protein. Therefore, whether 
orally tolerized hemophiliac mice would made antibodies 
after CFA immunization, and whether these antibodies 
would act as inhibitors and lead to resistance to treatment, 
was determined. 
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Hemophilia B mice were fed transgenic F.IX milk, or fed 
milk without FIX, every other day for two weeks. Two days 
after the last feeding, mice were immunized with h.FIX in 
CFA as described above. Nine days later, the tail vein was 
infused with a dose of F.IX just over the borderline for 
correcting the bleeding time (0.13 IU of functional hF.IX 
purified from the pig milk). This amount was chosen 
because it is in the range of F.IX most sensitive to inhibitors. 
Bleed times were measured six hours later. As shown in FIG. 
4, group 2 shows that this dose of hF.IX partially corrected 
the bleeding time (clotting occurred within 7-10 minutes). 
This clotting time is about twice as long as the 4-6 minutes 
clotting time of normal mice (see FIG. 7A), showing that 
0.13 IU of functional hFIX is a highly sensitive range of 
factor. Bleeding times in the immunized unfed F.IX hemo 
philia B mice (FIG. 4, group 3) were as long as those in mice 
not given factor (FIG. 4, group 1), showing that the anti 
bodies elicited by a single immunization with hFIX in CFA 
were highly inhibitory. However, the F.IX knock-out mice 
(hemophilia B mice) that were orally tolerized before immu 
nization (FIG. 4, group 4) showed little evidence of inhibi 
tors, as their bleeding times were only slightly longer than 
those of infused mice that had not been immunized. 
These results demonstrate that although orally tolerized 
mice produce antibodies when immunized with a very 
strong adjuvant, these antibodies do not lead to clinical 
resistance to hE.IX infusion. Therefore, the antibodies may 
be specific for denatured forms of the factor that occur in the 
adjuvant mixture and on ELISA plates, but the antibodies are 
not inhibitory to the native form of hF.IX in vivo. 
EXAMPLE 4 
Casein Oral Tolerance 
This example describes the methods used to determine if 
sheep would develop oral tolerance to casein using the 
methods described in EXAMPLES 1 and 2. Similar methods 
can be used to test any antigen of interest, such as F.VIII, 
F.IX, protein C, or insulin, in any animal/subject of interest. 
Lambs were raised on sheep or cow milk. After 3-4 
months, lambs were immunized with 0.5 mg sheep casein in 
CFA. Three and six weeks later, lambs were boosted with 0.5 
mg casein in incomplete Freund's adjuvant (IFA) (Sigma). 
Two months after the last immunization, peripheral blood 
mononuclear cells (PBMCs) were assayed for proliferation 
in the presence of titrated doses of sheep casein. Sheep 
PBMCs were isolated by centrifugating the blood through a 
lymphoprep gradient. Cells layered on the lymphoprep were 
collected and cultured in vitro in 96 well plates for four days 
in the presence of casein. Proliferation was measured by 
pulsing the cells with tritiated thymidine during the last eight 
hours of the culture and reading the results on a beta plate 
COunter. 
To measure casein-specific IgG in serum, maleic anhy 
dride activated polystyrene plates were coated with sheep 
casein (10 ug/ml) for 30 minutes at 37° C. and blocked with 
PBS 1% BSA (bovine serum albumin) for 30 minutes. After 
discarding the blocking buffer and five washes, serum 
samples (/10 diluted) were added into the wells and incu 
bated for two hours. The plates were subsequently washed, 
and horseradish peroxidase (HRP) conjugated rabbit anti 
sheep IgG (clone N126E, Southern Biotechnology Associ 
ates) was added and incubated for two hours, followed by 
TMP for color development, and plates subsequently read on 
an ELISA plate reader. 
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As shown in FIGS. 5A-5C, oral tolerance occurred in 
sheep. PBMCs from lambs that drank their mother's milk 
(sheep milk) did not proliferate in vitro to a sheep milk 
protein, casein, upon immunization as young adults (FIG. 
5A). In contrast, lambs that were fostered on cow's milk 
showed a vigorous proliferative response (FIG. 5B). In 
addition, orally tolerized lambs failed to make antibodies to 
casein (FIG.5C). 
EXAMPLE 5 
Orally Administered Clotting Factors Remain 
Functional 
Having demonstrated that oral tolerance to several differ 
ent antigens can be achieved, it was then demonstrated that 
the antigen remained functional after passing through the 
digestive system into the bloodstream. This example 
describes methods that were used to test the functionality of 
F.VIII and F.IX after they were orally administered. Similar 
methods can be used to identify a therapeutically effective 
amount of clotting factor necessary to increase hemostasis in 
a Subject, Such as in a hemophiliac. 
Factor IX 
Normal B10. A mice were fed either 0.5 ml of human F.IX 
in transgenic pig milk (which contained about 2.5 g/L of 
human F.IX; see Van Cott et al. 1999. Genet. Anal. 15:155 
60) or water alone. One hour after feeding, plasma was 
obtained from the mice and added to sheep T cells that are 
reactive against human F.IX, to determine if the plasma 
could stimulate the sheep PBMCs. Sheep T cells reactive 
against human F.IX were generated by immunizing sheep 
with human F.IX (100 ug) in CFA. PBMC from these sheep 
proliferate in a dose-dependent manner to purified human 
F.IX in vitro (FIG. 4A, dotted line) and therefore can be used 
to measure the amounts of human F.IX in blood samples. 
The plasma was diluted from about 1:10 and decrease in 
10-fold dilutions down to 1:107. Cells were cultured for four 
days in 96 well plates and pulsed with tritiated thymidine the 
last eight hours of the culture. As a control, sheep T cells 
were cultured in the presence of purified human F.IX. 
As shown in FIG. 6A, FIX present in the pig milk passed 
into the plasma after feeding. Sheep PBMC responded 
strongly to the fed mouse plasma (FIG. 6A, solid line), but 
not to plasma from unfed mice (FIG. 6A, bottom dashed 
line). It was determined that the fed mouse plasma contained 
about 6.7 ug/ml of human F.IX, indicating that about 0.1% 
of the fed F.IX entered the circulation. This result was 
confirmed by a sandwich ELISA to detect human F.IX in 
plasma after feeding (FIG. 6B). For the ELISA assay, 96 
well flat-bottom ELISA plates from PIERCE (Rockford, Ill.) 
were coated with sheep-anti-human F.IX polyclonal anti 
body (Cedarlane Laboratories, Ontario, Canada), then 
blocked with 10% BSA. Mouse plasma were diluted from 
/10 to /10,000 and added into the wells, incubated for two 
hours, washed with wash buffer, and then HRP-conjugated 
polyclonal goat anti-human F.IX antibodies (Cedarlane 
Laboratories) added for two hours. Color was developed by 
adding TMP, and results obtained using an ELISA plate 
reader. As shown in FIG. 6B, the amount of F.IX in the blood 
of F.IX-fed mice was similar when measured by ELISA to 
that measured by the PBMC (FIG. 6A) and that most F.IX 
passes into the circulation as intact protein. 
To determine if fed human F.IX retains its native form and 
functional ability to treat bleeding episodes, F.IX-containing 
transgenic pig milk (1.25 mg FIX) was fed to hemophilia B 
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mice (a F.IX knock-out obtained from Dr. Katherine High, 
Children’s Hospital of Philadelphia; approximately 20 g in 
weight) over a period of two months every other day and the 
effect on a bleeding defect determined. Bleeding time was 
measured by cutting the tip of the tail and waiting for it to 
clot. Normal mice clot in about four minutes (FIG. 7A, open 
squares). In contrast, hemophilia B mice do not stop bleed 
ing (FIG. 7A, open circles) and the tail tip is cauterized to 
stop bleeding after fifteen minutes. As shown in FIG. 7A, 
oral administration of F.IX immediately corrected the bleed 
ing defect (FIG. 7A, closed circles). In addition, this result 
is sustained for a period of at least two months (FIG. 7B). 
indicating that anti-FIX antibodies are not being generated, 
which allows the F.IX to remain functional. Therefore, oral 
administration of human F.IX is an effective treatment for 
bleeding, and does not induce inhibitory immunity, even 
following a long-term treatment. 
Factor VIII 
To demonstrate that hemophilia A, caused by the lack of 2 
functional F.VIII, could also be treated by oral administra 
tion of factor, milk from a transgenic pig engineered to 
secrete hE.VIII was fed to F.VIII knock-out mice. However, 
this treatment had no effect on oral tolerance or on clotting 
times. It was possible that the dose of F.VIII was too low, 
since this particular transgenic strain of pig does not produce 
large quantities of F.VIII (Paleyanda et al. Nature Biotech. 
15:971-5, 1997). Another explanation is that hF.VIII is 
almost 8 times larger than F.IX, with a molecular weight of 
nearly 240,000 kDa, which might make it difficult to pass 
into the bloodstream. 
To distinguish between these possibilities, the studies 
were repeated with commercially available F.VIII (Baxter) 
purified from human plasma (Red Cross Holland labs, 
Rockville, Md.). hF.VIII (100 g) was added to 0.5 ml of is 
water or cow's milk and fed to hemophilia A mice by 
gavage. Bleeding time was assayed 45 minutes later. As 
shown in FIG. 8A, the bleeding time was corrected in 
hemophilia A mice fed hE.VIII either in water or milk. 
Therefore, sufficient hF.VIII passes into the bloodstream in 
native form to function as a clotting factor, despite the size 
and complexity of the molecule. 
To determine whether hE.VIII might be passing through 
Small lacerations created by the gavage process, F.VIII was 
fed to the mice in a more physiologic way, by dissolving 400 
ugh F.VIII in 8 ml of commercial half cream/half milk and 
offering this to the mice in petri dishes. Three mice drank 
about 12 ml of this mixture in about 2 hours, delivering 
about 200 ug to each mouse daily. Bleeding time was 
assayed 45 minutes later. As shown in FIG. 8B, this method 
was also an effective method to treat the bleeding disorder. 
To demonstrate that feeding hF.VIII induces oral toler 
ance, hF.VIII was fed to hemophilia A mice (F.VIII knock 
out mice) in commercial half and half (600 ug F.VIII/12 ml 
of half and half) daily for eight days. Control mice were fed 
plain half and half. On day 10, mice were bled to determine 
the bleeding time (FIG. 8C, pre-imm), then immunized with 
hF.VIII in CFA as described in the Examples above. Seven 
days later, all mice were fed hF.V111-containing half-and 
half to determime if immunization-induced inhibitors would 
prevent the oral dose of F.VIII from functioning as a clotting 
factor. 
A single immunization did not inhibit the function of the 
orally administered factor in previously orally tolerized mice 
(FIG. 8C, closed circles), but did cause a loss of function in 
previously unfed controls (FIG. 8C, open circles). The test 
group was fed every other day, starting again from day 19 for 
20 
an additional 7 days. Mice were then boosted with hF.VIII 
in IFA, and again assayed for bleeding time 7 days later. 
Even after this second immunization with a strong adjuvant, 
the previously orally tolerized mice exhibited normal bleed 
5 ing times, while the un-tolerized controls did not. 
The mice were then sacrificed and checked for antibodies 
to F.VIII. Control mice had high levels of IgG2a antibodies 
(FIG. 8D, open circles), which is consistent with their 
inability to respond to treatment with hE.VIII. In contrast, 
the orally tolerized mice had barely detectable levels of 
IgG2a (FIG. 8D, closed circles). Although orally tolerized 
mice did have some IgG1 antibodies specific for hE.VIII, 
after immunization (FIG. 8C), these antibodies behaved like 
the similar antibodies in orally tolerized wild type mice. 
These antibodies are not inhibitors, as they did not affect the 
bleeding time (FIG. 8C). 
This is the first demonstration that missing clotting factors 
can be demonstrated in the circulation of hemophiliac mice 
as early as 45 minutes after feeding, and that the orally-fed 
O clotting factors are functional, as demonstrated by correction 
in bleeding time. Although it is commonly assumed that 
dietary proteins are digested completely to free amino acids 
within the lumen of the gastrointestinal tract and that only 
trace amounts of macromolecular fragments enter the cir 
culation having no clinical relevance, there is mounting 
evidence that suggests the opposite. The most compelling 
evidence showing that intact proteins or macromolecular 
fragments are absorbed is provided by the demonstration of 
antibodies to many food proteins that occur in the circulation 
of healthy individuals and experimental animals. For 
example, 5% of recombinant human erythropoietin (about 
40 kDa) fed to 10-day old rats was demonstrated in the 
serum as early as one hour after feeding (Miller-Gilbert et al. 
2001. Pediatr. Res. 50:261-7). Serum erythropoietin levels 
remained steady for up to 6 hours as opposed to the rapid 
peak and fall observed after intravenous administration. 
Although orally administered erythropoietin showed func 
tional activity in Hess mice by stimulation erythropoiesis, 
this could have been due to the stimulation of erythropoietin 
receptors on the enterocytes within the gastrointestinal tract. 
Similarly, gastrointestinal absorption of intact TGFB1 was 
demonstrated after administration (by gavage) of radiola 
beled TGFB into the stomachs of 5-day old pups (Letterio et 
al. 1994. Science 264:1936-8). Although the neonatal gut is 
very permeable to intact proteins, similar results were 
observed in adult animals. In mice, rats, and fish fed 
ovalbumin, casein or HRP respectively, between 0.005 to 
0.7% of the total fed amount was measured in the circulation 
either by ELISA or Western analysis (Gonnella et al. 2001. 
50 J. Immunol. 166:4456-64). Interestingly, the amount of 
antigen that passed into the circulation was much higher in 
B-cell deficient mice compared to wild type controls, Sug 
gesting that the lack of M cells does not affect the transport 
of proteins across the gut. 
Although both intravenous and oral administration of 
proteins results in detectable serum levels, antigen entry 
through the mucosa provides certain benefits. First, phar 
macokinetically, as opposed to a rapid rise and decline as 
seen after intravenous administration, oral administration 
provides relatively steady levels of the protein. Second, 
immunologically, it generates a gut-oriented immunity, 
which avoids inhibitory or rejecting antibodies. Therefore, 
feeding F.VIII and FIX in hemophilia A and B, respectively, 
is a simple, noninvasive and effective method of treating 
hemophilia. In addition, it induces oral tolerance, avoiding 
the generation of inhibitory antibodies and a vigorous T-cell 
response against missing clotting factors. 
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EXAMPLE 6 
Comparison of Oral Administration of Clotting 
Factors in Water and Milk 
To determine if the presence of milk was critical to 
achieve oral tolerance and maintain proper function of the 
clotting factor, the administration of F.VIII or F.IX in milk 
and water was compared. 
Purified F.VIII from human serum was orally adminis 
tered to hemophilia A mice (F.VIII knock out; Dr. Kang, U. 
of Iowa.) in cow's milk or in water. Mice were fed 100 ug 
of F.VIII (antihemophilic factor, Baxter, Deerfield, Ill.) by 
gavage in 0.5 ml of water or cow's milk. Bleeding time was 
measured as described above, 45 minutes after feeding. As 
shown in FIG. 8A, feeding F.VIII derived from human 
plasma that is added into cow's milk or water corrects 
bleeding time in hemophilia A mice. Therefore, the presence 
of milk when orally administering F.VIII is not critical. 
To determine if the presence of milk was critical to 
achieve oral tolerance to FIX, normal B10. A mice were fed 
with low (10-20 ug F.IX/feed) or high (2500 ug F.IX/feed) 
does of human F.IX in pig milk or as purified plasma-derived 
human F.IX (Sigma) reconstituted in water (10-20 ug F.IX/ 
feed) every other day for a total of five feeds. Control mice 
were fed no F.IX. Two days later, mice were immunized with 
0.5ug human F.IX emulsified in CFA at the base of the tail. 
Seven days later, the amount of T cell proliferation was 
determined using the methods described in EXAMPLE 1. 
As shown in FIGS. 9A and 9B, mice fed as little as 20 lug 
F.IX in milk (FIG. 9A) were almost completely unrespon 
sive, while T cells from mice fed with FIX in water (FIG. 
9B) retained a small amount of activity (about 3% of unfed 
controls). However, administration of F.IX in water or milk 
resulted in better oral tolerance than no administration of 
F.IX. 
In summary, a dose of 100 ug F.VIII/20 g body weight 
(about 5 mg/kg), orally administered every day (or every 
other day), can be used to increase hemostasis, thus treating 
hemophilia A. In addition, a dose of 1 mg FIX/20 g body 
weight (about 50 mg/kg), orally administered every day (or 
every other day), is expected to increase hemostasis thus 
treating hemophilia B. However, it is possible that lower 
doses can be used, or that higher doses may be required in 
a particular subject, in order to obtain a successful treatment 
of hemophilia. 
EXAMPLE 7 
Determination of Parameters for Low Dose Oral 
Tolerance 
To identify optimal conditions to achieve low dose oral 
tolerance to human F.IX delivered in transgenic pig milk, the 
following methods can be used. Similar methods can be used 
to determine the conditions for other antigens, including 
F.VIII, insulin, and protein C, in humans. 
Lambs can be used as an experimental model. Sheep are 
an outbred species and, like humans (but unlike mice), their 
immune system becomes functional during the last trimester 
of pregnancy. They are also easier than mice to bottle-feed. 
The architecture of sheep intestines during the first 24-48 
hours of life is designed to collect maternal antibodies from 
colostrum, with very high levels of Fc receptors that have a 
half-life of about 24 hours. Therefore, feeding of F.IX milk 
is started 48 hours after birth, when the gut has settled. 
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Lambs are fed 0.3 mg F.IX/kg of animal/day, the amount 
of protein shown to induce low dose tolerance in 20 g mice 
(FIGS. 1A-1C). The effective dose range in mice is 0.001 to 
0.1 mg for OVA (0.05-5 mg/kg) and 0.003 to 0.1 mg/day for 
F.IX (0.15-0.5 mg/kg). Lambs are fed daily for three weeks 
with sheep milk Supplemented with pig milk containing 
human F.IX (see EXAMPLE 5). A parallel control group of 
lambs is Supplemented with normal pig milk containing no 
human F.IX. Milk is collected, frozen immediately, and 
thawed just before use. Experiments with mice demonstrate 
that continuous daily feeding is the most effective way of 
inducing oral tolerance. 
Sheep can be immunized as early as two weeks of age. At 
three weeks of age, half the lambs are immunized with F.IX 
in CFA after the feedings are completed and then boosted 
two weeks later with F.IX in IFA. A dose of 100 ug human 
FIX is Sufficient to prime young ewes for a Subsequent 
proliferative and antibody response. Lambs are tested for 
various types of immunity against F.IX after each immuni 
Zation. 
Three assays can be used to detect immune responses 
against F.IX. First, the amount of peripheral blood mono 
nuclear cell proliferation can be determined. One week and 
two weeks after immunization, 10-20 ml of venous blood is 
collected by jugular Venipuncture, the mononuclear cells 
fractionated using Percoll gradients and Subsequently cul 
tured in vitro in the presence of titrated amounts of F.IX, and 
assay for proliferation as described in EXAMPLES 1, 2 and 
4. 
Second, serum F.IX specific antibody titers can be deter 
mined. From each blood sample collected, serum is 
extracted. Dilutions of the serum are added to ELISA plates 
(Pierce) coated with human F.IX (10 ug/ml). After a two 
hour incubation, the plates are washed with wash buffer, 
then incubated with polyclonal HRP-conjugated goat anti 
human F.IX antibodies (Cedarlane Laboratories) for two 
hours. For color development TMP is added and then the 
plates are read in an ELISA plate reader. Antibodies of 
different classes can be identified using the sandwich ELISA 
method described in EXAMPLES 4 and 5. 
Third, a factor IX inhibitor assay (Bethesda Assay) can be 
conducted. This functional assay measures the amount of 
inhibitor antibody in serum. The Bethesda assay is an in 
vitro functional assay performed by mixing plasma contain 
ing unknown amounts of inhibitors (test plasma) with nor 
mal plasma to determine how the test plasma prolongs the 
APTT of the normal plasma. 
Lambs fed human F.IX should not generate a strong 
specific proliferative response, and should not develop anti 
bodies against F.IX. If antibodies are produced, they will be 
of the secretory IgA type and will not be inhibitory against 
F.IX. 
It is possible that the determined effective dose in sheep 
or other subjects (such as humans) may differ from that in 
mice. If feeding 0.3 mg/kg/day F.IX does not result in oral 
tolerance, experiments can be repeated using a titration of 
higher and lower doses of F.IX, to determine the appropriate 
dose. In addition, it can also be determined whether feeding 
during the first 48 hours of life can enhance oral tolerance. 
EXAMPLE 8 
Determination of Parameters for High Dose Oral 
Tolerance 
To determine parameters that are helpful to achieve opti 
mal high dose oral tolerance to human F.IX delivered in 
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transgenic pig milk, the following methods can be used. 
Similar methods can be used to determine the parameters for 
other antigens, including F.VIII, insulin, and protein C. 
Although low dose tolerance induces remarkable reduc 
tions in cellular responses, it may allow for some antibody 
production. Though antibodies are unlikely to result in 
rejection of cells expressing a FIX transgene, they may 
inhibit the secreted product. Therefore, tolerance can also be 
induced by feeding high doses of F.IX. This approach has 
not been feasible in the past because of the extraordinarily 
high cost of purified FIX. However, induction of oral 
tolerance does not require purified antigen. As experiments 
in sheep illustrate (FIGS. 5A-5C), newborns become toler 
ant of milk proteins even when the proteins are given as 
mixtures in normal milk. The tolerizing ability of unpurified 
transgenic pig milk containing 2.5 g/L F.IX (see EXAMPLE 
5) in the native situation where piglets feed continuously is 
tested. 
Non-transgenic piglets are fostered onto transgenic moth 
ers and allowed to drink ad libitum until weaned. A control 
group of foster littermates is fostered onto non-transgenic 
control mothers. Two days after the animals are weaned, half 
of the piglets in each group are Subcutaneously immunized 
with F.IX (0.1 mg) in CFA and two weeks later, boosted with 
F.IX in IFA. Half of the piglets will be un-immunized as 
controls. One and two weeks after each immunization vari 
ous classes of immunity will be determined as described 
above in EXAMPLE 7. 
Piglets that drank F.IX containing milk from transgenic 
mothers are expected to be tolerant to FIX. This tolerance is 
tested by Subsequently immunizing these piglets to human 
FIX in CFA as described in the examples above. Tolerance 
is achieved if there is decreased antibody formation and T 
cell proliferation in these piglets compared to piglets fos 
tered onto a non-transgenic mother using the methods 
described in the examples above. 
EXAMPLE 9 
Oral Tolerance in Hemophiliac Puppies 
This example describes procedures that can be used to 
develop oral tolerance to clotting factors in hemophiliac 
puppies. The method specifically outlines methods for test 
ing tolerance to FIX in hemophiliac B puppies, but those 
skilled in the art will understand from the teachings herein 
that similar methods can be used to test for tolerance to 
F.VIII in hemophiliac A puppies, or for tolerance to any 
antigen in any subject having an antigen-deficiency disease. 
A canine model of hemophilia A is available (Giles et al. 
1982. Blood 60:727-30; and Giles et al. 1984. Blood 63:451 
6). Hemophilia A was diagnosed in a miniature Schnauzer 
dog and inbreeding and crossbreeding produced 16 hemo 
philic animals. Five animals developed potent antibodies to 
canine F.VIII. In each case, the antibodies recognize both 
canine and human, but not porcine F.VII. Following inhibi 
tor development, infusion of canine cryoprecipitate was 
hemostatically ineffective and F.VIII recovery at 30 minutes 
is negligible. 
Two canine models of hemophilia B are available. In the 
Chapel Hill dog colony, hemophilia B is due to a missense 
mutation, and inhibitor formation in response to canine 
plasma or gene therapy maneuvers is relatively uncommon 
(Evans et al. 1989. Proc. Natl. Acad. Sci. USA. 86:10095 
9). However, for the Auburn dog colony, where disease is 
due to a Small deletion that results in an early stop codon 
(Mauser et al. 1996. Blood. 88:3451-5), inhibitor formation 
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is more frequent. In both types of mutations, inhibitors to 
canine F.IX can be induced by various means including 
repeated injection of purified canine F.IX, or injection of 
vector expressing canine F.IX. The rise in inhibitor antibod 
ies correlates with fall of plasma F.IX levels (Herzog et al. 
1999. Nat. Med. 5:56-63). Both colonies of dogs readily 
form inhibitory antibodies following infusion of human 
F.IX. 
To assess the effect of oral tolerance on the development 
of clotting factor inhibitors after immunization, canine mod 
els for hemophilia are used. F.IX is administered orally to 
normal puppies and to puppies with hemophilia B (Auburn 
dog colony) and their spontaneous immune responses 
against F.IX analyzed. 
The optimal feeding dose of F.IX found to prevent devel 
opment of inhibitory antibodies is used (see EXAMPLES 
5-8). Normal and hemophilia B puppies are divided into two 
groups: one group is fed F.IX-containing transgenic pig 
milk, and the other group fed non-transgenic pig milk to 
serve as controls. Puppies are fed for six weeks until they are 
fully weaned. 
The puppies are then infused with 50 IU/kg human F.IX 
intravenously daily for two weeks, starting two days after 
weaning, or earlier if necessary to control bleeding. The 
generation of inhibitor antibodies after repeated intravenous 
administration of human F.IX has been well established in 
the canine model (Evans et al. 1989. Proc. Natl. Acad. Sci. 
USA. 86:10095-9). The course of the disease is followed, 
periodically assaying for inhibitory antibodies using the 
Bethesda assay (see EXAMPLE 7), especially after FIX 
infusions due to bleeding episodes. 
PBMC proliferation and serum antibody titers against 
F.IX are also compared between control and experimental 
animals, as described in EXAMPLE 4, except that the in 
vitro assays are modified to Suit canine cells. For example, 
IMDM plus canine serum is a superior medium for canine 
proliferation assays whereas RPM plus fetal calf serum 
serves well for sheep. 
It is expected that the intact antigen will gain access to the 
bloodstream after feeding, as was obtained for F.IX in mice 
(EXAMPLE 5). To test for F.IX in plasma samples from 
F.IX-fed hemophilia B and normal puppies, methods 
described in EXAMPLE 5 are used. 
To determine if the F.IX antigen remains functional after 
oral administration, a functional assay is performed. For 
example, an APTT assay which measures the intrinsic 
coagulation activity of the plasma can be used. 
Therefore, in addition to orally tolerizing the immune 
system, it is determined whether Small amounts of func 
tional F.IX can reach the blood and help prevent bleeding 
episodes, thus increasing hemostasis. 
It is expected that oral administration of F.IX by feeding 
will induce oral tolerance and prevent the development of 
inhibitory antibodies, as well as remain functional in the 
blood, and therefore increase hemostasis and serve as a 
treatment for hemophilia. 
EXAMPLE 10 
Oral Administration Followed by In Vivo Gene 
Expression 
To demonstrate that administration and Subsequent 
expression of a FIX-containing transgene can be used to 
treat hemophilia, adeno-associated vectors containing a FIX 
gene can be used. 
US 7,220,718 B2 
25 
After orally tolerizing puppies to FIX as described in 
EXAMPLE 9, adeno-associated viral vectors are used to 
introduce the human F.IX gene into hemophiliac puppies 
orally tolerized to human F.IX to increase hemostasis. Simi 
lar methods can be used in human hemophiliacs. 5 
Methods for generating an introducing transgenes into a 
subject are well known in the art. In addition, viral vectors 
for introducing a clotting factor into a subject are known. 
Examples of methods and vectors that can be used to 
introduce a clotting factor into a subject, include, but are not 10 
limited to those disclosed in: Stein et al., 2001. Mol. Ther: 
3:850-6: Miller et al., 2001. N. Engl. J. Med. 344:1782-4: 
Emilien et al., 2000. Clin. Lab. Haematol. 22:313-23: 
Andrews et al., 2001. Mol. Ther. 3:329-36; Fabb et al., 2000. 
Curr. Opin. Mol Ther. 2:601-6; and Lillicrap, 2000. Hae- 15 
matologica 85 (10 Suppl): 108-12, as well as other docu 
ments cited herein. 
Following administration of the vector, F.IX levels in 
serum, as well as immunity to FIX, are monitored as 
described in EXAMPLES 5 and 7, over a period of one year 20 
or until the factor disappears, whichever comes first. 
It is expected that oral administration of a clotting factor 
by feeding will induce oral tolerance and prevent the devel 
opment of inhibitory antibodies, such that when the factor is 
Subsequently expressed recombinantly in the Subject, the 
recombinant protein will not be inactivated by anti-clotting 
factor antibodies. This will result in functional clotting 
factor in the blood, and therefore increase hemostasis and 
serve as a treatment for hemophilia. 
25 
30 
EXAMPLE 11 
Oral Tolerance and Treatment in Humans 
This example describes methods that can be used to 35 
induce tolerance to FIX in a human hemophiliac. Similar 
methods can be used to induce oral tolerance to any antigen 
of interest in a human subject, for example F.VIII, insulin 
and protein C. 
Among hemophilia patients that form inhibitors, the inci 
dence of patients with large deletions is known (deletion/ 
total inhibitor production=0.5). However, due to the cost of 
widespread genetic screening, and the lack of practical 
consequence to the management of hemophilia patients, the 
incidence of inhibitor producers among those with large 
deletions is not known (inhibitor production/large dele 
tions). 
The patient group most likely to benefit from treatment 
are children that have no F.IX, thus making them particularly 
prone to making inhibitors. After determining the F.IX levels 
in plasma of a hemophiliac child, patients having undetect 
able levels are further tested to determine whether they have 
a large F.IX deletion. From this study, the incidence of 
inhibitor producers among those who have large deletions 
can be determined. 
From studies on hemophiliac puppies, patients with large 
deletions are believed to be particularly prone to making 
inhibitors and thus particularly at risk of becoming refrac 
tory to replacement therapy. 60 
Hemophiliac children are orally tolerized by oral admin 
istration (feeding) of F.IX-containing transgenic milk. Alter 
natively, purified F.IX can be administered orally in any 
medium suitable for oral administration, including water. 
The immune response to F.IX during the course of the 65 
disease is monitored as described in EXAMPLE 7. In 
addition, the amount of functional F.IX in the blood, the 
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formation of antibodies against F.IX and PBMC prolifera 
tion are monitored as described above. 
In addition, hemostasis is monitored, using an APTT 
assay described in EXAMPLE 7 or a bleeding time assay. 
Treatment is successful if hemostasis is increased relative to 
hemostasis prior to oral administration of the clotting factor, 
or relative to untreated hemophiliacs. 
EXAMPLE 12 
Oral Tolerance Followed by In Vivo Gene 
Expression 
As an alternative to continually orally administering a 
clotting factor to a Subject to increase hemostasis, once oral 
tolerance is achieved, long term treatment of the clotting 
disorder can be achieved by expressing the deficient clotting 
factor in vivo. Similar methods can be used to treat any 
antigen-deficiency disease. 
The present disclosure provides methods of expressing a 
protein in a cell or tissue in vivo. In one embodiment, 
transfection of the cell or tissue occurs in vitro. In this 
example, the cell or tissue (Such as a graft) is removed from 
a Subject and then transfected with an expression vector 
containing a cDNA encoding the protein of interest. The 
transfected cells will produce functional protein and can be 
reintroduced into the subject. In another embodiment, a 
nucleic acid encoding the protein of interest is administered 
to a Subject directly, and transfection occurs in vivo. 
The methods disclosed herein can be used to treating a 
Subject with an antigen-deficiency disease such as a subject 
having hemophilia A or B. Such a method would increase 
hemostasis (decrease blood clotting time) in hemophiliacs or 
Subjects having other defects in blood clotting. 
The scientific and medical procedures required for human 
cell transfection are now routine. The public availability of 
numerous protein and cDNA sequences allows the devel 
opment of human (and other mammals) in vivo gene expres 
sion based upon these procedures. Immunotherapy of mela 
noma patients using genetically engineered tumor 
infiltrating lymphocytes (TILs) has been reported by 
Rosenberg et al. (N. Engl. J. Med. 323:570-8, 1990). In that 
study, a retrovirus vector was used to introduce a gene for 
neomycin resistance into TILS. A similar approach may be 
used to introduce a clotting factor cDNA into hemophiliacs. 
In some embodiments, a method of treating Subjects 
which under express a functional protein, or in which greater 
functional protein expression is desired, is disclosed. These 
methods can be accomplished by introducing a gene coding 
for the desired protein into a Subject. A general strategy for 
transferring genes into donor cells is disclosed in U.S. Pat. 
No. 5,529.774, incorporated by reference. Generally, a gene 
encoding a protein having therapeutically desired effects is 
cloned into a viral expression vector, and that vector is then 
introduced into the target organism. The virus infects the 
cells, and produces the protein sequence in vivo, where it has 
its desired therapeutic effect. Zabner et al. (Cell 75:207-16, 
1993). 
It may only be necessary to introduce the genetic or 
protein elements into certain cells or tissues. However, in 
Some instances, it may be more therapeutically effective and 
simple to treat all of a subjects cells, or more broadly 
disseminate the vector, for example by intravascular (i.v.) 
administration. 
The nucleic acid sequence encoding at least one thera 
peutic agent, such as a clotting factor, is under the control of 
a suitable promoter. Suitable promoters which may be 
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employed include, but are not limited to, the gene’s native 
promoter, retroviral LTR promoter, or adenoviral promoters, 
such as the adenoviral major late promoter; the CMV 
promoter; the RSV promoter; inducible promoters, such as 
the MMTV promoter; the metallothionein promoter; heat 
shock promoters; the albumin promoter, the histone pro 
moter; the O-actin promoter, TK promoters: B19 parvovirus 
promoters; and the ApoAI promoter. However the scope of 
the disclosure is not limited to specific foreign genes or 
promoters. 
The recombinant nucleic acid can be administered to the 
subject by any method which allows the recombinant 
nucleic acid to reach the appropriate cells. These methods 
include injection, infusion, deposition, implantation, or topi 
cal administration. Injections can be intradermal or Subcu 
taneous. The recombinant nucleic acid can be delivered as 
part of a viral vector, Such as avipox viruses, recombinant 
vaccinia virus, replication-deficient adenovirus strains or 
poliovirus, or as a non-infectious form Such as naked DNA 
or liposome encapsulated DNA, as further described in 
EXAMPLE 13. 
EXAMPLE 13 
Viral Vectors for In Vivo Gene Expression 
Adenoviral vectors include essentially the complete aden 
oviral genome (Shenk et al., Curr: Top. Microbiol. Immunol. 
1 11:1-39, 1984). Alternatively, the adenoviral vector is a 
modified adenoviral vector in which at least a portion of the 
adenoviral genome has been deleted. In one embodiment, 
the vector includes an adenoviral 5.' ITR, an adenoviral 3' 
ITR, an adenoviral encapsidation signal; a DNA sequence 
encoding a therapeutic agent; and a promoter for expressing 
the DNA sequence encoding a therapeutic agent. The vector 
is free of at least the majority of adenoviral E1 and E3 DNA 
sequences, but is not necessarily free of all of the E2 and E4 
DNA sequences, and DNA sequences encoding adenoviral 
proteins transcribed by the adenoviral major late promoter. 
In another embodiment, the vector is an adeno-associated 
virus (AAV) such as described in U.S. Pat. No. 4,797,368 
(Carter et al.) and in McLaughlin et al. (J. Virol. 62:1963-73, 
1988) and AAV type 4 (Chiorini et al. J. Virol. 71:6823-33, 
1997) and AAV type 5 (Chiorini et al. J. Virol. 73:1309-19, 
1999) 
Such a vector can be constructed according to standard 
techniques, using a shuttle plasmid which contains, begin 
ning at the 5' end, an adenoviral 5' ITR, an adenoviral 
encapsidation signal, and an E1a enhancer sequence; a 
promoter (which may be an adenoviral promoter or a foreign 
promoter); a tripartite leader sequence, a multiple cloning 
site (which may be as herein described); a polyA signal; and 
a DNA segment which corresponds to a segment of the 
adenoviral genome. The DNA segment serves as a substrate 
for homologous recombination with a modified or mutated 
adenovirus, and may encompass, for example, a segment of 
the adenovirus 5' genome no longer than from base 3329 to 
base 6246. The plasmid can also include a selectable marker 
and an origin of replication. The origin of replication may be 
a bacterial origin of replication. A desired DNA sequence 
encoding a therapeutic agent can be inserted into the mul 
tiple cloning site of the plasmid. 
Examples of vectors which can be used to practice the 
methods disclosed herein include those disclosed in: WO 
95/27512 to Woo et al., WO 127303 to Walsh et al.: U.S. Pat. 
No. 6,221,349 to Couto et al., U.S. Pat. No. 6,093,392 to 
High et al. 
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EXAMPLE 1.4 
Production of Sequence Variants 
Disclosed herein methods for treating antigen-deficiency 
diseases by oral administration of the appropriate antigen or 
protein. It is understood by those skilled in the art that use 
of non-native antigen sequences (such as polymorphisms, 
fragments, or variants) can be used to practice the methods 
of the present disclosure, as long as the distinctive functional 
characteristics of the antigen are retained. For example, F.IX 
or F.VIII variants can be used to practice the methods 
disclosed herein if they retain their ability to increase 
hemostasis. This activity can readily be determined using the 
assays disclosed herein, for example those described in 
EXAMPLES 5 and 9. In yet other embodiments, F.IX or 
F.VIII has the distinct characteristic of being reduced in 
patients Suffering from hemophilia. 
This disclosure facilitates the use of DNA molecules, and 
thereby proteins, derived from a native protein but which 
vary in their precise nucleotide or amino acid sequence from 
the native sequence. Such variants can be obtained through 
standard molecular biology laboratory techniques and the 
sequence information disclosed herein. 
DNA molecules and nucleotide sequences derived from a 
native DNA molecule can also be defined as DNA sequences 
which hybridize under stringent conditions to the DNA 
sequences disclosed, or fragments thereof. Hybridization 
conditions resulting in particular degrees of stringency vary 
depending upon the nature of the hybridization method and 
the composition and length of the hybridizing DNA used. 
Generally, the temperature of hybridization and the ionic 
strength (especially the Na" concentration) of the hybrid 
ization buffer determines hybridization stringency. Calcula 
tions regarding hybridization conditions required for attain 
ing particular amounts of stringency are discussed by 
Sambrook et al. (Molecular Cloning: A Laboratory Manual, 
Cold Spring Harbor, N.Y., 1989, Chapters 9 and 11), herein 
incorporated by reference. Hybridization with a target probe 
labeled with “P-dCTP is generally carried out in a solution 
of high ionic strength such as 6xSSC at a temperature that 
is about 5-25° C. below the melting temperature, T. An 
example of stringent conditions is a salt concentration of at 
least about 0.01 to 1.0 M Na ion concentration (or other 
salts) at pH 7.0 to 8.3 and a temperature of at least about 30° 
C. for short probes (e.g. 10 to 50 nucleotides). Stringent 
conditions can also be achieved with the addition of desta 
bilizing agents such as formamide. For example, conditions 
of 5xSSPE (750 mM NaCl, 50 mM. Na phosphate, 5 mM 
EDTA, pH 7.4) at 25-30° C. are suitable for allele-specific 
probe hybridizations. 
The degeneracy of the genetic code further widens the 
Scope of the present disclosure as it enables major variations 
in the nucleotide sequence of a DNA molecule while main 
taining the amino acid sequence of the encoded protein. For 
example, the amino acid Ala is encoded by the nucleotide 
codon triplet GCT, GCG, GCC and GCA. Thus, the nucle 
otide sequence could be changed without affecting the 
amino acid composition of the encoded protein or the 
characteristics of the protein. Based upon the degeneracy of 
the genetic code, variant DNA molecules may be derived 
from a cDNA molecule using standard DNA mutagenesis 
techniques as described above, or by synthesis of DNA 
sequences. DNA sequences which do not hybridize under 
stringent conditions to the cDNA sequences disclosed by 
virtue of sequence variation based on the degeneracy of the 
genetic code are also comprehended by this disclosure. 
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Clotting factor variants, fragments, fusions, and polymor 
phisms will retain the ability to increase hemostasis, as 
determined using the assays disclosed herein, for example 
by performing an APTT assay (EXAMPLE 9) or a bleeding 
time assay. Variants and fragments of a protein may retain at 
least 70%, 80%, 85%, 90%, 95%, 98%, or greater sequence 
identity to a protein amino acid sequence and maintain the 
functional activity of the protein as understood by those in 
skilled in the art. Examples of clotting factor variants, 
include, but are not limited to those disclosed in U.S. Pat. 
No. 6,221,349 to Couto et al., U.S. Pat. No. 4,877,614 to 
Andersson et al.; EP 770396 to Zimmermann et al.; U.S. Pat. 
No. 6,093,392 to High et al.; and EP 0294.910 to van Ooyen 
et al. 
EXAMPLE 1.5 
Recombinant Expression of Proteins 
With publicly available cDNA and corresponding amino 
acid sequences, as well as the disclosure herein of variants, 
fragments and fusions thereof, the expression and purifica 
tion of any publicly known protein by standard laboratory 
techniques is enabled. The purified protein can be used for 
patient therapy. For example, mammals that produce recom 
binant F.VIII or F.IX in their milk are known (see U.S. Pat. 
No. 5,880,327 to Lubon et al. and Van Cott et al. 1999. 
Genet. Anal. 15:155-60, respectively), and can be used to 
practice the methods disclosed herein. However, one skilled 
in the art will understand that the orally administered 
clotting factor can be produced in any cell or organism of 
interest, and purified prior to administration to a subject, as 
an alternative to feeding the Subject milk containing the 
recombinant clotting factor. 
Methods for producing recombinant proteins are well 
known in the art. Therefore, the scope of this disclosure 
includes recombinant expression of any antigen/protein. For 
example, see U.S. Pat. No. 5,342,764 to Johnson et al.; U.S. 
Pat. No. 5,846,819 to Pausch et al.: U.S. Pat. No. 5,876,969 
to Fleer et al. and Sambrook et al. (Molecular Cloning. A 
Laboratory Manual, Cold Spring Harbor, N.Y., 1989, Ch. 
17, herein incorporated by reference). 
In addition, methods for producing recombinant clotting 
factors are known, for example as disclosed in EP 0294910 
(and references therein); EP 0160457; EP 0253.455; EP 
O150735; U.S. Pat. No. 6,221,349 to Couto et al.; U.S. Pat. 
No. 5,804,420 to Chan et al. and U.S. Pat. No. 4,770,999 to 
Kaufman et al. 
EXAMPLE 16 
Peptide Modifications 
Orally administered proteins can be modified using a 
variety of chemical techniques to produce derivatives having 
essentially the same activity as the unmodified peptides, and 
optionally having other desirable properties. For example, 
carboxylic acid groups of the peptide, whether carboxyl 
terminal or side chain, can be provided in the form of a salt 
of a pharmaceutically-acceptable cation or esterified to form 
a C-C ester, or converted to an amide of formula NRR 
wherein R and R2 are each independently H or C-C alkyl, 
or combined to form a heterocyclic ring, Such as a 5- or 
6-membered ring. Amino groups of the peptide, whether 
amino-terminal or side chain, can be in the form of a 
pharmaceutically-acceptable acid addition salt, Such as the 
HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric 
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and other organic salts, or may be modified to C-C alkyl 
or dialkyl amino or further converted to an amide. 
Hydroxyl groups of the peptide side chain can be con 
verted to C-C alkoxy or to a C-C ester using well 
recognized techniques. Phenyl and phenolic rings of the 
peptide side chain can be substituted with one or more 
halogen atoms, such as F, Cl, Br or I, or with C-C alkyl, 
C-C alkoxy, carboxylic acids and esters thereof, or 
amides of Such carboxylic acids. Methylene groups of the 
peptide side chains can be extended to homologous C-C, 
alkylenes. Thiols can be protected with any one of a number 
of well-recognized protecting groups, such as acetamide 
groups. Those skilled in the art will also recognize methods 
for introducing cyclic structures into the peptides disclosed 
herein to select and provide conformational constraints to 
the structure that result in enhanced stability. For example, 
a carboxyl-terminal or amino-terminal cysteine residue can 
be added to the peptide, so that when oxidized the peptide 
will contain a disulfide bond, generating a cyclic peptide. 
Other peptide cyclizing methods include the formation of 
thioethers and carboxyl- and amino-terminal amides and 
esterS. 
To maintain a functional peptide, particular peptide vari 
ants will differ by only a small number of amino acids from 
a peptide. Such variants can have deletions (for example of 
1-3 or more amino acids), insertions (for example of 1-3 or 
more residues), or substitutions that do not interfere with the 
desired activity of the peptide. Substitutional variants are 
those in which at least one residue in the amino acid 
sequence has been removed and a different residue inserted 
in its place. In particular embodiments, such variants have 
amino acid substitutions of single residues, for example 1, 3, 
5 or even 10 substitutions in a protein. 
Peptidomimetic and organomimetic embodiments are 
also disclosed herein, whereby the three-dimensional 
arrangement of the chemical constituents of Such peptido 
and organomimetics mimic the three-dimensional arrange 
ment of the peptide backbone and component amino acid 
sidechains in the peptide, resulting in Such peptido- and 
organomimetics of a clotting factor having the ability to 
increase hemostasis. For computer modeling applications, a 
pharmacophore is an idealized, three-dimensional definition 
of the structural requirements for biological activity. Pep 
tido-and organomimetics can be designed to fit each phar 
macophore with current computer modeling Software (using 
computer assisted drug design or CADD). See Walters, 
“Computer-Assisted Modeling of Drugs, in Klegerman & 
Groves, eds., 1993, Pharmaceutical Biotechnology, Inter 
pharm Press: Buffalo Grove, Ill., pp. 165-174 and Principles 
of Pharmacology (ed. Munson, 1995), chapter 102 for a 
description of techniques used in CADD. 
EXAMPLE 17 
Pharmaceutical Compositions and Modes of 
Administration 
The pharmaceutically effective carriers useful herein are 
conventional. Remington's Pharmaceutical Sciences, by 
Martin, Mack Publishing Co., Easton, Pa., 15th Edition 
(1975), describes compositions and formulations suitable for 
pharmaceutical delivery. 
Oral Administration of Antigens and Proteins 
In an embodiment in which an antigen, such as a clotting 
factor, is administered to a Subject, the antigen is delivered 
enterally, for example orally (e.g., by feeding), or rectally 
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(e.g., by Suppository). The present disclosure also provides 
pharmaceutical compositions which include a therapeuti 
cally effective amount of a clotting factor alone or with a 
pharmaceutically acceptable carrier. Furthermore, the phar 
maceutical compositions or methods of treatment can be 
administered in combination (or separately) with one or 
more other therapeutic treatments, such as other agents that 
increase hemotasis. Embodiments of the disclosure com 
prising medicaments can be prepared with conventional 
pharmaceutically acceptable carriers, adjuvants and counte 
rions as would be known to those of skill in the art. 
The antigen can be administered in combination with at 
least one, for example one or more pharmaceutically effec 
tive carriers, such as a pharmaceutically and physiologically 
acceptable fluid. Examples of pharmaceutically effective 
carriers include, but are not limited to milk, water, physi 
ological saline, balanced salt solutions, aqueous dextrose, 
sesame oil, glycerol, ethanol, combinations thereof, or the 
like, as a vehicle. The carrier and composition can be sterile, 
and the formulation Suits the mode of administration. In 
addition to biologically-neutral carriers, pharmaceutical 
compositions to be administered can contain minor amounts 
of non-toxic auxiliary Substances, such as wetting or emul 
Sifying agents, preservatives, and pH buffering agents and 
the like, for example sodium acetate or Sorbitan monolau 
rate. 
The composition can be a liquid solution, Suspension, 
emulsion, tablet, pill, capsule, Sustained release formulation, 
or powder, but not a liposome also containing a protease 
inhibitor. For Solid compositions (e.g., powder, pill, tablet, 
or capsule forms), conventional non-toxic Solid carriers can 
include, for example, pharmaceutical grades of mannitol, 
lactose, starch, Sodium saccharine, cellulose, magnesium 
carbonate, or magnesium Stearate. The composition can be 
formulated as a Suppository, with traditional binders and 
carriers such as triglycerides. 
The amount of antigen, Such as a clotting factor, effective 
in the treatment of a particular disorder or condition, such as 
hemophilia, will depend on the nature of the disorder or 
condition, and can be determined by standard clinical tech 
niques. In addition, in vitro assays can be employed to 
identify optimal dosage ranges (see EXAMPLES 7 and 8). 
The precise dose to be employed in the formulation will also 
depend on the seriousness of the disease or disorder, and 
should be decided according to the judgment of the practi 
tioner and each subject's circumstances. Effective doses can 
be extrapolated from dose-response curves derived from in 
vitro or animal model test systems. 
The disclosure also provides a pharmaceutical pack or kit 
comprising one or more containers filled with one or more 
of the ingredients of the pharmaceutical compositions. 
Optionally associated with Such container(s) can be a notice 
in the form prescribed by a governmental agency regulating 
the manufacture, use or sale of pharmaceuticals or biological 
products, which notice reflects approval by the agency of 
manufacture, use or sale for human administration. Instruc 
tions for use of the composition can also be included. 
Administration of Nucleic Acid Molecules 
In an embodiment in which a nucleic acid is employed to 
allow expression of a nucleic acid in a cell, the nucleic acid 
is delivered intracellularly (e.g., by expression from a 
nucleic acid vector or by receptor-mediated mechanisms). In 
one embodiment, a nucleic acid encodes for an antigen, Such 
as a clotting factor. 
Various delivery systems for administering a nucleic acid 
are known, and include encapsulation in liposomes, micro 
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particles, microcapsules, receptor-mediated endocytosis 
(Wu and Wu, J. Biol. Chem. 1987, 262:4429-32), and 
construction of therapeutic nucleic acids as part of a retro 
viral or other vector. Methods of introduction include, but 
are not limited to, intradermal, intramuscular, intraperito 
neal, intravenous, Subcutaneous, intranasal, and oral routes. 
The compounds may be administered by any convenient 
route, for example by infusion or bolus injection, by absorp 
tion through epithelial or mucocutaneous linings (e.g., oral 
mucosa, rectal, vaginal and intestinal mucosa, etc.) and may 
be administered together with other biologically active 
agents. Administration can be systemic or local. Pharma 
ceutical compositions can be introduced into the central 
nervous system by any Suitable route, including intraven 
tricular and intrathecal injection; intraventricular injection 
may be facilitated by an intraventricular catheter, for 
example, attached to a reservoir, Such as an Ommaya 
reservoir. 
Liposomes fuse with the target site and deliver the con 
tents of the lumen intracellularly. The liposomes are main 
tained in contact with the target cells for a sufficient time for 
fusion to occur, using various means to maintain contact, 
Such as isolation and binding agents. Liposomes can be 
prepared with purified proteins or peptides that mediate 
fusion of membranes, such as Sendai virus or influenza 
virus. The lipids may be any useful combination of known 
liposome forming lipids, including cationic lipids, Such as 
phosphatidylcholine. Other potential lipids include neutral 
lipids, such as cholesterol, phosphatidyl serine, phosphatidyl 
glycerol, and the like. For preparing the liposomes, the 
procedure described by Kato et al. (J. Biol. Chem. 1991, 
266:3361) can be used. 
Where the therapeutic molecule is a nucleic acid, admin 
istration can be achieved by an appropriate nucleic acid 
expression vector which is administered so that it becomes 
intracellular, e.g., by use of a retroviral vector (see U.S. Pat. 
No. 4,980.286), or by direct injection, or by use of micro 
particle bombardment (e.g., a gene gun; Biolistic, Dupont), 
or coating with lipids or cell-surface receptors or transfect 
ing agents, or by administering it in linkage to a homeobox 
like peptide which is known to enter the nucleus (see e.g., 
Joliot et al., Proc. Natl. Acad. Sci. USA 1991, 88:1864-8), 
etc. Alternatively, the nucleic acid can be introduced intra 
cellularly and incorporated within host cell DNA for expres 
Sion, by homologous recombination. 
The vector pcDNA, is an example of a method of intro 
ducing the foreign cDNA into a cell under the control of a 
strong viral promoter (CMV) to drive the expression. How 
ever, other vectors can be used (see EXAMPLES 13 and 15). 
Other retroviral vectors (such as pRETRO-ON, Clontech), 
also use this promoter but have the advantages of entering 
cells without any transfection aid, integrating into the 
genome of target cells only when the target cell is dividing 
(as cancer cells do, especially during first remissions after 
chemotherapy) and they are regulated. It is also possible to 
turn on the expression of a nucleic acid by administering 
tetracycline when these plasmids are used. 
Other plasmid vectors, such as pMAM-neo (Clontech) or 
pMSG (Pharmacia) use the MMTV-LTR promoter (which 
can be regulated with steroids) or the SV10 late promoter 
(pSVL, Pharmacia) or metallothionein-responsive promoter 
(pBPV. Pharmacia) and other viral vectors, including retro 
viruses. Examples of other viral vectors include adenovirus, 
AAV (adeno-associated virus), recombinant HSV, poxvi 
ruses (vaccinia) and recombinant lentivirus (such as HIV). 
These vectors achieve the basic goal of delivering into the 
target cell the cDNA sequence and control elements needed 
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for transcription. The present disclosure includes all forms 
of nucleic acid delivery, including synthetic oligos, naked 
DNA, plasmid and viral, integrated into the genome or not. 
Having illustrated and described methods for treating 
hemophilia A or B by oral administration of a therapeutically 
effective amount of F.VIII or F.IX, respectively, it should be 
apparent to one skilled in the art that the disclosure can be 
modified in arrangement and detail without departing from 
Such principles. In view of the many possible embodiments 
to which the principles of our disclosure may be applied, it 
should be recognized that the illustrated embodiments are 
only particular examples of the disclosure and should not be 
taken as a limitation on the scope of the disclosure. Rather, 
the scope of the disclosure is in accord with the following 
claims. We therefore claim as our invention all that comes 
within the scope and spirit of these claims. 
We claim: 
1. A method for increasing hemostasis in a Subject having 
hemophilia B in which clotting factor IX (FIX) is deficient 
and wherein the subject does not have F.IX inhibitors, 
comprising orally administering to the Subject a therapeuti 
cally effective amount of the F.IX sufficient to induce oral 
tolerance of the F.IX and supply exogenous F.IX to the 
Subject, thereby increasing hemoslasis in the Subject and 
treating the hemophilia B, wherein the F.IX is not present in 
a liposome. 
2. The method of claim 1, wherein the hemophilia B is a 
result of impaired expression of the F.IX, and the F.IX is 
administered as long as the hemophilia B persists. 
3. The method of claim 1, wherein increasing hemostasis 
comprises decreasing blood clotting time. 
4. The method of claim 1, wherein the F.IX is adminis 
tered in absence of an anti-immune therapy. 
5. The method of claim 1, wherein the therapeutically 
effective amount of F.IX is at least 5 mg of F.IX per 1 kg of 
Subject daily. 
6. The method of claim 1, wherein the therapeutically 
effective amount of F.IX is at least 50 mg of F.IX per 1 kg 
of subject daily. 
7. The method of claim 1, wherein the subject is a 
mammal. 
8. The method of claim 7, wherein the mammal is a 
human. 
9. The method of claim 1, wherein the F.IX is present in 
milk obtained from a non-human transgenic mammal 
expressing recombinant F.IX. 
10. The method of claim 9, wherein the mammal is a pig. 
11. The method of claim 3, wherein the blood clotting 
time is measured using an activated partial thromboplastin 
time (APTT) assay. 
12. The method of claim 1, wherein oral administration is 
achieved by feeding the subject a therapeutically effective 
amount of the clotting factor. 
13. The method of claim 12, wherein the F.IX is a 
recombinant F.IX present in milk of a non-human transgenic 
mammal. 
14. The method of claim 1, wherein the F.IX is present in 
a pharmaceutically effective carrier. 
15. The method of claim 14, wherein the pharmaceuti 
cally effective carrier is water. 
16. The method of claim 14, wherein the pharmaceuti 
cally effective carrier is milk. 
17. A method for increasing hemostasis and inducing oral 
tolerance in a Subject having hemophilia B in which clotting 
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factor IX (F.IX) is deficient and wherein the subject does not 
have F.IX inhibitors, consisting of orally administering to 
the subject the therapeutically effective amount of F.IX and 
at least one pharmaceutically acceptable carrier which is not 
a liposome. 
18. A method for orally administering a recombinant 
clotting factor IX (F.IX) to a subject for treatment of 
hemophilia B in which F.IX is deficient, wherein the subject 
does not have inhibitors to FIX, comprising orally admin 
istering a milk containing recombinant F.IX to the Subject at 
a therapeutically effective amount Such that hemostasis in 
the subject is increased and oral tolerance of F.IX is induced, 
thereby treating the hemophilia B. 
19. The method of claim 18, wherein the milk comprises 
at least 2 g recombinant clotting factor IX per liter of milk. 
20. The method of claim 19, wherein the milk is obtained 
from a non-human transgenic mammal. 
21. The method of claim 20, wherein the mammal is a pig. 
22. The method of claim 21, wherein the recombinant 
F.IX is present at a concentration of about 2 g per liter of the 
milk. 
23. A method for orally administering a recombinant 
clotting factor IX (F.IX) to a subject for treatment of 
hemophilia B in which F.IX is deficient wherein the subject 
does not have inhibitors to FIX, comprising: 
expressing the recombinant F.IX in a non-human mammal 
such that the F.IX is expressed in milk of the mammal; 
and 
orally administering the milk in which the F.IX has been 
expressed to the subject at a therapeutically effective 
amount Such that blood cloning time in the Subject is 
reduced and oral tolerance of the FIX is induced, 
thereby treating the hemophilia B. 
24. A method for orally administering a recombinant F.IX 
protein to a subject for treatment of hemophilia B, wherein 
the subject does not have inhibitors to FIX, comprising 
orally administering milk containing recombinant F.IX pro 
tein to the subject at a therapeutically effective amount such 
that blood clotting time in the subject is reduced and oral 
tolerance of the recombinant F.IX protein is induced, 
thereby treating the hemophilia B. 
25. A method of increasing hemostasis in a mammal 
having hemophilia B, comprising orally administering to the 
mammal 5-50 mg/kg/day of factor IX, wherein factor IX is 
not present in a liposome, and wherein the factor IX induces 
oral tolerance of the factor IX and Supplies exogenous factor 
IX to the mammal, thereby increasing hemostasis in the 
mammal. 
26. A method of increasing hemostasis in a mammal 
having hemophilia B, comprising orally administering to the 
mammal every other day 5-50 mg/kg of factor IX, wherein 
factor IX is not present in a liposome, and wherein the factor 
IX induces oral tolerance of the factor IX and supplies 
exogenous factor IX to the mammal, thereby increasing 
hemostasis in the mammal. 
27. The method of claim 25, wherein the factor IX is 
recombinant factor IX present in milk of a non-human 
transgenic mammal. 
28. The method of claim 26, wherein the factor IX is 
recombinant factor IX present in milk of a non-human 
transgenic mammal. 
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